This article is 10.1111/all.13642 doi: lead todifferences version between this andthe ofPleasecite article Version Record. this as been and throughtypesetting, proofreadingwhich may thecopyediting, process, pagination This article undergon has for and accepted been publication 2 1 Palomares O KF Chung Roth An EAACI Taskf respiratory diseases C Articletype : Position Paper CRISTIANAPROF. STELLATO(Orcid ID 0000: FRANCESCAPROF. LEVI KIANDR. FAN GAETANOPROF. CARAMORI (Orcid ID : 0000 RODOLFODR. BIANCHINI (OrcidID : 0000 FRANZISKADR. ROTH Molecular Cell Biology Group, National Heart & Lung Institute, Imperial College London, UK Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary of University the of Institute Research Messerli Interuniversity The Medicine, Comparative Medicine Accepted Article molecule small and biologicals omparing - atr F Walter
7 , Diamant Z Diamant , Vienna, Medical University Vienna and University Vienna, Vien
3 , , Puzzovio PG orce CHUNG (Orcid : ID 0000 1 protected rights by All copyright. reserved. Acc I Adcock , o n - Immunopharmacology WALTER (Orcid ID : 0000
, 9, 8, -
SCHAFFER (Orcid ID : 0000 M Eguiluz 1
3 2 , Redegeld, ,
Benito - Gracia I Gracia - Villalvilla - 0001 F
1 - 4 0003 , Van Esch Van , 1 0 - - (TIPCO) , Knol , 7101 - 0002 0002 - - C 0001 0351 - - 3
1426) - 1294 - Bacii R Bianchini , 9807 E 0003 position paper
- - 1 5005 B 6937) 1 , Kolios A Kolios ,
1 -
- 8355) 4 - 327X) 0620 , Stellato, C - 9228)
- drug
2810) e full peer review but has e not review fullpeer 1
Bemr L Bjermer , 1 2
, Levi ,
16
therapies * § n -
Schaffer a, Austria 4 Caramori , F
1 3 o chronic for , Nocentini G Nocentini , G
5 Cr L Cari ,
6 6 , , This article is Keywords 16 1 1 1 1 1 9 8 7 6 5 4 3
4 3 2 1 0 Department of of Department Department of Medicine, Section of Pharmacology, University of Perugia, Perugia Italy Department of Respiratory ofDepartment Allergology,research,Medicine allergy and and Lung Allergy, Asthmaand Unità Operativa Complessa di Pneumologia, Dipartimento di Scienze di Dipartimento Pneumologia, di Complessa Operativa Unità University of Groningen, University Medical Center Groningen,Center Medical UniversityGroningen, of University Experimental Studies Medicine at National He National at Medicine Studies Experimental Unive Complutense Chemistry, of School Biology, Molecular and Biochemistry of Department ofDepartment Immunology, University Hospital Zurich, Zurich, Switzerland Netherlands Research Institute of Malaga (IBIMA). Málaga, Spain Hospital, Lund, Sweden Pharmacology Brompton & Harefield NHS Trust, London, UK delle Immagini Morfologiche eFunzionali (BIOMORF), Università degli Studi di Messina, Italy COPD Competence center, Lund University, Lund, Sweden Madrid, Madrid, Spain Salerno, Italy University, TheNetherlands Jerusalem, Israel Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", Medica "Scuola Dentistry and Surgery Medicine, of Department Departments of Immunology and Dermatology/Allergology, University Medical Center Utrecht,The Center Medical University Dermatology/Allergology, and Immunology of Departments nttt fr rg eerh Sho o Pamc, aut o Medicine of Faculty Pharmacy, of School Research, Drug for Institute Accepted Utrecht Sciences, Pharmaceutical of Department Pharmacology, of Division Science, of Faculty Biomedical and Málaga of Hospital University Regional Laboratory, Research and Unit Allergy Article : biologicals, small molecule
protected rights by All copyright. reserved. , , Groningen, The Netherlands Respiratory Medicine and Allergology, Institute for Clinical Science, Skane University Skane Science, Clinical for Institute Allergology, and Medicine Respiratory
drugs , asthma,, COPD
art & Lung Institute, Imperial College London College Imperial Institute, Lung & art
, antibodies
Department of Clinical Pharmacy and Pharmacy Clinical of Department
Biomediche, Odontoiatriche e Odontoiatriche Biomediche, Te erw nvriy of University Hebrew The ,
University of Salern of University
& rsity of rsity
Royal o , This article is Antonios GAKolios, MD Edward Knol, PhD, ORCID0000 Francesca Levi Ibon Eguiluz Zuzana Diamant, MD KianFan Chung, MD, Luigi Cari, GaetanoCaramori, Leif Bjermer, MD, ORCID 0000 Rodolf Cristina IanAdcock,M PhD, ORCID 0000 versionwas 2018 Salerno in meeting a during compiled and developed discussed, further were They molecule small and diseases related cur review and regulation immune of mechanisms basic on breakthroughs recent basicscientists,pharmacologists,and physicians computational biologists 2017 in established § Medica Salernitana", University of Salerno, Salerno, Italy. * Footnotes: orsodn author: Corresponding Accepted Article was EAACI of Section Immunology the within (TIPCO) Immunopharmacology of Force Task The rent, upcoming andupcoming rent, ) Te oiin paper position The . o Bianchini, PhD, ORCID0000 Benito PhD,
- approvedby all Force Task Members. Gracia, MD - - Schaffer, Villalvilla protected rights by All copyright. reserved. ORCID 0000 . . The different topics different The MD, PhD, drug therapeutic drug , DSc o onc sinit and scientist connect to
MD paradigm
, PhD PhD , , PhD,
Cristiana , , ORCID0000 PhD
PhD, - draft draft 0003 , ORCID
ORCID 0000 - 0002 - ORCID: 0001 - 0003 - - shifting therapeutic approaches for allergy and clinical immunologyandclinicalallergy for therapeuticapproachesshifting a teefe rcruae ad rtcly prie utl h final the until appraised critically and recirculated thereafter was 0698 tlao Dprmn o Mdcn, ugr ad etsr "Scuola Dentistry and Surgery Medicine, of Department Stellato, - - 0000 0003 3441 - 7368 -
approaches, - for this for 2101 0001 0000 - 3872 - - - - 0002 0351 8099 - 0003 9820 - - - 8843, 7101 0003
first - -
- lncas ih h dfeet cetfc backgrounds scientific different the with clinicians 9807 6937
0620
- -
1426 0133 position paper position were a were -
- 327X 2810
- 0100 [email protected] ssigned and drafted by drafted and ssigned
, based on comparison of biologicalsof comparison on based , -
with the task of examining of task the with
a hi apiain in application their uthors’ (February 24 (February subgroups. - 25,
- -
This article is The (UK), Trust CharitableAimwell The (USA), Fund Endowed Memorial GuttermanEmalie of funding Accepted b funding received report. Force Task this of development the in support financial their for EAACI thank to like would authors The (EAACI). Funding: been also has and diseaserenumerated for speaking engagements. BvE is partly employed by Nutricia Research. pulmonary obstructive chronic and pha asthma the for of treatments regarding meetings Board Advisory in participating for honoraria received Sanofi and Novartis from boards AstraZe Amgen, Therapeutics, Allergy from fees lecture received OP company; pharmaceutical related any Alk Amgen, Leo, Actelion, Novartis, AbbVie, for advisor and/or speaker,investigator, an as Astra fromfeeslectures ALK, from advisory fees Aquilon, ALK, companies: pharmaceutical Boehringer following AstraZeneca, the from years) consultancy 3 for past honoraria the received (within also activities ZD companies; pharmaceutical and biotech various for Group Menarini GSK, Ingelheim, Boehringer Biofutura, Zeneca, Astra from meetings scientific to participate to accommodation and Articletravel for grants and/or fees Lecture and/or grants educational unrestricted has GC manuscript. this COI: Betty vanEsch, PhD, ORCID 0000 Cristiana Stellato, MD, PhD, ORCID0000 Franziska Roth Frank Redegeld,A PhD, ORCID PierGiorgio Puzzovio, MSc, ORCID0000 Oscar Palomares, PhD, ORCID0000 Giuseppe Nocentini,
IMA, CBV, GN, RB, PGP, LB, LC, FAR, CS FRW, ea Imntk Nvri, Sanofi Novartis, Inmunotek, neca,
The Task Force was financed by the European Academ European the by financed was Force Task The - Walter, PD PhD, ORCID 0000 protected rights by All copyright. reserved. Uiest o Msia l Rgoe S Regione la Messina, of University y CS received funding from University of Salerno and Salerno of University from funding received CS MD, PhD, - nehi, ied HAL Gilead, Ingelheim, 0000 ORCID 0000 . ZD is employed by a CRO (QPS CRO a by employed is ZD . - - 0001 Genzyme. CBV received the FPU fellowship from MINECO, KFC has KFC MINECO, from fellowship FPU the received CBV Genzyme. - - - 0003 Abello, and does not hold any shares or other financial interest ininterest financial other or shares any hold not does and Abello, 0001 - 9961 - - 0001 0002 - - 4516 8830 - - 0002 ezm ad tlegns n priiae i advisory in participated and Stallergenes and Genzyme - - 0001 750X - - 7961 1294 - - 0369 - 7960 - Zeneca, NovartisZeneca, 5209 - ha -
5005 leg, Sanofi Allergy, - - 0423 ve 8355
-
no conflictsno intere of 0488 Abbott, Janssen, Eli Lilly, MSD, Pfizer, Celgene,Pfizer, MSD, Lilly, Eli Janssen, Abbott, - 9228
cla Iay n Astra and Italy icilia,
y for Allergy and Clinical Immunology Clinical and Allergy for y - - , NL) who performs phase I/II studies I/II phase performs who NL) Genzyme
Chiesi and DiaterandChiesi Campania - st regardingst the subject of eeeo. E received IEG Regeneron. - Zeneca mcuia industry rmaceutical
; Region AGAK has servedhas AGAK
;
L received FLS , Italy , ; ; GC - This article is DNA CysLT CXCR2 CXCL2 CRTH2= DP2 COX COPD CNS CDC CD CCR2 c BBB ALOX5 AE ADCC ACO 5 Abbreviations SAF2017 Austrian the from funding received F4606 SFBproject FWF Fund Science RB (ISCIII); III Carlos Salud de Instituto the of (CM17/00140) Sc Israel - - KIT LO
Accepted Article
- ec Fudto (rn 213/05); (grant Foundation ience 84978
protected rights by All copyright. reserved. - R) .
Cyclooxygenase chronic obstructive pulmonary disease central nervous system complement Clusterof differentiation C CD117/stem cell growth factor receptor/ tyrosine blood brain barrier 5 adverse event antibody Asthma 5 deoxyribonucleic acid Cysteinyl leukotriene receptor Chemokine (C Chemoattractant Receptor C - - - - lipoxygenase lipoxygenase C chemokine X - C motif chemokine receptor2/interleukin receptor8 - COPD overlap - dependent cell - dependent cytotoxicity -
X
receptortype 2
- - C motif) ligand 2 B28
;
OP received funding from MINECO ( SAF2014 ( MINECOfrom fundingreceived OP
-
mediatedcytotoxicity - E rcie the received IEG homologous molecule expressedon
Ro Hortega“ „Rio
- proteinkinase,
udn scheme funding T -
Helpertype 2 cells - 52706 - R andR
This article is LT1 LAMA LABA JAK ILC 1/2/3 IL IL IgE IFN H1 GR Gq GOLD GM GINA GATA3 FEV1 FeNO FDA EMA EGFR DP2 DP1 - 4Rα 4Rα
Accepted Article
-
CSF
protected rights by All copyright. reserved. Interleukin4 Receptoralpha interleukin ImmunglobulinE interferon glucocorticoid receptor guanine nucleotide Global initiative chronic for Obstructive Lung Disease Granulocyte Global INitiative Asthma for GATA binding protein 3 forced expiratory volume in one second fractional expired nitric oxide Food and Drug Administration EuropeanMedicines Agency Epidermal growth factor receptor prostaglandinD2 receptor ProstaglandinD2 receptor 1 cys long long janus kinase innate lymphoid cells group 1/2/3 H1 H1 receptor - leukotriene receptor - - acting muscarinic acting beta
-
macrophage colony -
agonists - binding protein G subunit - agonists
2
- stimulating factor
This article is Accepted WHO ULABA TXA2 TSLP TNF Th9 Th2 Th17 Th1 STAT ArticleSMD PTGIR PI3K PGD2 PDE p110d MR MMP MAPK mAbs
- protected rights by All copyright. reserved. thromboxane A2 thymic tumor necrosis factor alpha T helpercells that produce interleukin T helper 2 T helpercells that produce interleukin Signal Transducer and Activator of Transcription proteins Small prostaglandinI2 receptor phosphoinositide 3 prostaglandinD2 phosphodiesterase phosphoinositide 3 muscarinic receptor matrix metalloprotease Mitogen monoclonal antibodies World HealthWorld Organization ultra T helper1 - long molecule drug stromal lymphopoietin - activatedprotein kinase - acting beta
- - kinase kinasePI3K delta
- agonists
- - 9 17
This article is discovery of understanding tak this estimated billion €9.8 at estimated loss productivity annual worldwide pulmoobstructive worldwide non chronic, common most ap Introduction gaps order of applications A both compartment intracellular the pharmaceutical a severe severe as such therapies standard by controlled not conditions Antibody process. expensive d for therapies networks molecular with and asthma as such diseases airway Chronic Abstract
vlpet f e sf ad fetv teais for therapies effective and safe new of evelopment im oe limited more proaching pandemic proportions pandemic proaching
Acceptedes Article health crisis health
f hs review this of in convenience and hi comorbidities their longer, costs more andis less successful codn t te ol Hat Organization Health World the to According I to
n asthma, while in other other whilein asthma, current treatment for
the highlight how the how highlight and (2) at (1)
p about 3 about
distinct . ast decade with
The economic of cost asthma across Europe is estimated etr eiiin f agtbe pathways. targetable of definition better protected rights by All copyright. reserved.
SMD research and development and research , c , mat Sal molecule Small impact. nary disease (COPD)disease nary urrent development of new safe and effective therapies for respiratory diseases respiratory for therapies effective and safe new of development urrent 49 the s o compare to is s .
- 4% of the total healthcare budgethealthcaretotal the of 4% phenotypes not controlled by current by controlled not phenotypes
underlying
lower million and antibody and oeua ntok udryn ara dsae pathogenesis disease airway underlying networks molecular , ,
high
er sgiiat udn n ulc elh Increased health. public on burden significant a bear y should be integrated be should y - - cost based (biological) therapies (biological) based omncbe ies aog children among disease communicable s chronic inflammatory - throughput technology and systems biology (3) by
s . inflammatory
de solely
n contrast and (1) - based iey as livery inflammatory was .
W
in Europe in drug ith regard to respiratory diseases, respiratory to regard ith . 251 million, 251
treatment S respiratorydiseases chronic obstructive pulmonary disease ( disease pulmonary obstructivechronic MDs than for otherdiseases either
(SMD) iwy ies need disease airway h dsic pamclgcl rpris n clinical and properties pharmacological distinct the
(6) expand biologic expand
for respiratory diseases. (4, 5) (4,
. an
In addition, the t the addition, In -
strategies, their limitation their strategies, ae therapies based their optimal utilization optimal their
placing - (WHO) such such
rl r topical or oral approximately 38.6 billion Euros billionapproximately 38.6 are . n hs cnro ietfcto o specific of identification scenario, this In In 2016, the 2016, In treatment successful eprtr dsae is diseases respiratory
crnc nlmaoy iess are diseases inflammatory chronic , it ,
such as COPD, biologicals COPD, as such as allergic al
s’ therapeutic targets by reaching by therapeutictargets s’ the
(7) and s ly otal direct costs for COPD are COPD for costs direct otal regimens.
at
in fourth . global prevalence global represent - o e rnltd no new into translated be to
based
n refractory and €17 billionper yearwith an treating affects have
bronchial
leading cause of deathof cause leading
and rapid formulation s On the other the On 358
certain and challenges and n cie il in field active an to COPD n arduous an ly appreciation
ilo people million
fill the critical the fill expand a , sthma is the is sthma
eosinophilic (4)
respiratory aiding ) are of , together , offer , .
Despite chronic having ed hand,
and our the , ing
of in
This article is response “T2” the in involved pathways are responses both Asthma in treatment pathophysiology chronic respiratory diseases 1. chronic respiratory diseases classes drug side dataclinical andReviewing pharmacological and strengths of applications clinical and of review apply characteristics clinical and pharmacological asthma for investigation clinical under or compare of objective main The performance therapeutic clinical and pharmacological biochemical, sought molecule small conditions income disease aim should We phenotypicendotypicand determinants
Accepted Disease) Lung Obstructive chronic for initiative (Global GOLD Article a A chronic bothare COPD and Asthma and endotypes Phenotypes, of success the with Along sthma and COPD, -
after in immune in after - tm is sthma patients rather than symptom control, yet remaining yet control, symptom than rather COPD overlap COPD
and contrastand the
as well as wellas guidelines -
such as severe asthma, severe as such and highlight and main features of features main
limitations protected rights by All copyright. reserved. for drug (SMD) drug .
and usually targeted therapies that fulfil that therapiestargeted effector cellseffector for these diseasesfor
the this lncl features clinical (ACO) - al mediated diseases mediated
and
though it does not represent a single disease entity s major biologicalsandmajor - soitd with associated position paper position
-
. calls for potential avenues for expanding for avenues potential based therapies re therapies based n provide and
SMD is characterized by persistent airflow limitation airflow persistent by characterized is they can be used together to create powerful combinationspowerful create to togetherused be can they the two the - :
eosinophils and mast andeosinophils
and imres n sha n COPD and asthma in biomarkers multiple biologicals systemic lupus erythematosus, rheumatoid arthritis rheumatoid erythematosus, lupus systemic
diseases are biological ifr considerably differ of
an ly effective ly from the from inflammatory
asthma and COPD isasthmaCOPDand
reviewed n/r COPD and/or (8, 9) (8,
and targeted predominant up ta i, n dpie epne rvn y h cytokine the by driven response adaptive an is, (that
present
- , the ambitious goal of modif of goal ambitious the o tetn allergic treating for SMD to - we . by -
based - These t These to date - EAACI side compare safe,
– yearly characteristics as well as features limiting their limiting features as well as characteristics therapeutic options therapeutic based therapeuticbased strategies
an active field in drug R&D drug in field active an
airway cells list of of list reveals
therapeutic therapeutic approaches wo drug classes drug wo available andavailable n re t hglgt o ter distinctive their how highlight to order in Task Force Task T
in GINA( in h Tbe 1 n 2) and 1 (Tables .
their , ILC2 2,
As such, specific key targets for asthmafor targets key specific such, As the distinct pharmacologicalpropertiesdistinct the
diseases, though their though diseases, opud ad nie sources online and compounds oneof
common unmet needs unmet common therapeutic app therapeutic
- Global INitiativeGlobal Asthma for documents
: on strategies
our and and u affordable, especially for low for especiallyaffordable, ncovering Immunopharmacology .
ha
major researchmajor challenges In particular, upon particular, In ying the ying other T
ve h (11) with several features of features several with 9 Te definitions The .
- powerful and distinct and powerful respectively , driven . - .
ih hi specific their with immune currently availablecurrently h cmlxt of complexity the lications and natural course natural natural history,natural
remain highly remain for these twothese for
cell and
[ - Ref.
mediated for immune cancer 4 11) (4,
a brief a
§ Imai]
these )
(10)
is to is and and
of
- - . . . .
This article is goals todisease SMDs and biologicals including options, therapeutic targeted of application order targeted COPD and asthma oxide) nitric expired inflammation airway of biomarkers used widely exacerbations, of occurrence mutually by than rather individual, same exclusive COPD subtypes the within degrees varying in coexisting traits disease that revealed cohorts COPD across exists. prevalence and definition phenotypes their regarding consensus universal and management specify to help may that COPD for T v s 16) clinicalfeatures inflammation airway eosinophilic ill an have asthma with patients the of half least at both phenotypes asthma clinic recognized is asthma high’ receptor (CRTH2) cells Th2 on expressed molecule homologous receptor chemoattractant receptors respective their milieuproduced by lymphocytes, Th2 ILCsother and cell types) tarted to reveal to tarted alidation theseof mechanisms will reveal new targets for future h
Accepted ArticleT 1, .
However, h asthma, to contrast In
o ep identi help to N 17, ILC1 and ILC3 and ILC1 17, o single - ramn response treatment n sbye o CP eaebtos ae en described been have exacerbations COPD of subtypes and protected rights by All copyright. reserved.
nuevsd clustering unsupervised - or clinicalortraits modifying strategies. bio T2 and non and T2 marker is marker as
yn targetable fying n idcd sputum. induced and lhuh they although
(22) with recurrent exacerbations and bloo exacerbationsand recurrent with cells a wl as well as , . - pathogenic mechanisms in mechanisms pathogenic sufficiently
T2
(24) h eouin u evolution the as well as well as
has nothas ally subphenotypes of severe asthma severe of subphenotypes
. a been has
Advancing as h COPD the
taiy patients stratify disease
clarified severe allergic asthma (IgE asthma allergic severe (DP2) receptor (PGD2) D2 prostaglandin the ae o ciia vrals n ifamtr markers inflammatory and variables clinical on based specific with
Overall, ikd o otcseod insensitivity corticosteroid to linked neutrophils dr ramn o te mortality the or treatment nder
pathways
u kolde o knowledge our continuous by characterised better is heterogeneity underlyingmechanisms in asthmatics in and sensitiveandthe predict to iiain exist limitations - provide defined ,
none COPD ,
(8) rv te eeomn ad personalized and development the drive
; a prognostic outcome are outcome prognostic a
can are ’ s are such such T2 imilarly, clustering on clinical features clinical on clustering imilarly, d
interventions disease f -
and sputum and
low blood eosinophils, blood
associated to a greater exten greater a to associated effectively - (1 mediated) or or mediated) as 7) ’ for
IgE andIL . phenotype o Prospective and longitudinal and Prospective f (19 current
asthma ahgnss s pivotal is pathogenesis
progression of progressionof - 21) Clinically
predict eosinophil (18) n etn treatment extend and - , risk 4, IL
sever biomarkers
oee c however . (14) as anticipatedas (12, 13) (12,
- FeNO (23) 5 and5 IL a , . ,
e eosinophilic e n
C lacking ia also
many . utrn o lustering individual . However, .
. ( COPD n n and h most The fractional The lustering
- term n both in 13 and13 ,
t COPD as no as
, t , (15, ‘T2 with has on ed he ly in f - - -
This article is example, essential early or preclinical in currently COPD for n pathophysiology reduc and progression disease and disease no are there and currently no ta T2 counts. eosinophil ( blood high by defined inflammation eosinophilic anti and mepolizumab) and (reslizumab for (omalizumab) add patients, population asthma difficult complianceIf of use of measures objective providing features morbid anti based based inflammation and and the control COPD and asthma of goal 2. Main d ovel upilumab Accepted- Article high asthma. asthma. high
clinical reassessment drug targeted For COPD, the stakes are stakes the COPD, For T 2. therapy once
he majority of patients withasthma achieve - p - a to
harmacological . side that respond poorly to poorly respond that , t o nrae h od of odds the increase to
- rials with anti with rials Current therapeuticapproachesCurrent
- oto atm cn al in fall can asthma control although ) inflammatory symptoms andreducesymptoms to (17) -
a which - - - and inhalation technique aretechniqueinhalationand n ilgcl hrpe at therapies biological on effects
d rgeted (25) therapies protected rights by All copyright. reserved.
ay formulations ay n carries and and the and have For patients with non with patients For relieverdrug hs wt high with those . is
lre ubr of number large a H effective particularly in severe eosinophilic asthma eosinophilicsevere in particularlyeffective (4, 1 (4, therapies available owever, en addressed. been - f
IL - , eatures (29) lack of of lack
modifying therapies modifying 1) hrpe ee when even therapies aimat - current treatment strategies, as recommended by GINA and GOLD, and GINA by recommended as strategies, treatment current 5 .
h lret burden largest the (30) . Bothregimens
s - S some patients remain refractory to control by current by control to refractory remain patients some
stage clinical development clinical stage
(26, 27) (26, trikingly, even during stable disease biomarker
prevent
of e glucocorticoid use and
total hs drugs these b h mraiy rate mortality the iologicals the risk of exacerbations, risk of the develop ,
to higher as higher anti -
eosinophilic inflammation and non and inflammation eosinophilic , h ctgr o svr asthma severe of category the
eu IE ees with levels IgE serum which ing
M ad biologicals and SMD none of the of none as theirendotypic definitionis currently unclear. opine s improved is Compliance GINA - : good for many but leaving out too many too out leaving but many for good : s for s
IL - satisfactory, IL
includecontroller - exacerbation 5R - . rcpo atbd (erlzmb fr hs with those for (benralizumab) antibody receptor 5 and ing
lead patient current Current tp ae o aalbe uh s anti as such available now are 5 Step therapy. rgesn truh h dvlpet process development the through progressing deec, rpr s o ihlr hrp ad co and therapy inhaler of use proper adherence,
of
antibodies easier SMD
the s sha obdt ad costs and morbidity asthma
to (11) biologicals ir s stratification
. anti then this then
therapeutic goal therapeutic improved
-
for therapeutic goals to
s
Severe asthma Severe (Table 3) ,
- (10) T or reducor - use a inflammatory therapies are not effective not are therapies inflammatory e complexity he (31) sthma
drugs lower ietd gis dfeet targets different against directed .
legc asthma allergic and
pursued
group of patientsof group B in eosinophilic COPD eosinophilic in control with conventional therapy conventional with control etter endotypic characterization endotypic etter . y opig naes ih devices with inhalers coupling by
and ing
targeting have airway oe fetv ihlr and inhalers effective more
their severity COPD
s (28) - exists in exists
, besides smoking cessation smoking besides , so far so
limited
with the current lo aeld as labelled also - s / n anti An allergic
heterogeneity of of heterogeneity
damage will also be available foravailable be also will
airflowobstruction t , reatment
ha r anti or
. the ~ s
initially labelled aslabelledinitially
5% of the asthma the of 5% o ti gop of group this For disease reached approvalreached - , IL ,
development inorder to slow . . loss of of loss - glucocorticoid showed R antibody 4Rα - - The common The IL . g antibody IgE
-
antibody 5
refractory guideline there are there function either COPD . is to is
and the For are
of is - - - .
This article is high avoidingthus potentially undesirable effects on their to due conditions physiological under membranes weight molecular cell cross not do they as targets intracellular desirable or molecules soluble systemic action and glucocorticoids da benralizumab) SMDs of those than scaling SMDs than costs monetary associated well having Conversely made be can copies identical therefore, well is modification Any well simple, is structure act without receptor the bind to able cytokines mutated or cytokines specific for receptors soluble as targets specific against directed and organisms certain for suitability their and body the in formulations action of mode their behave, they how produced, biologicalsSMDand eosinophilic severe asthma. eosinophilic lesser a il
Accepted Articleivation y. ;
-
up however, are Biologicals 2. or no or I ally . resp n . b ,
, Their
purification
, hr i srnt i dfeecs c differences: in strength is There molecules
S asthma. the mostly ( MDs Table reduction
via protected rights by All copyright. reserved. (33)
i aoy diseases ratory l
ow molecular weight and chemical structure chemical and weight molecular ow d many (36) intravenous
vlpet f ilgcl rqie rltvl cmlx rcse wt higher with processes complex relatively requires biologicals of evelopment r defined are . s 4 by oral formulations, oral by bronchodilators .
)
thus , Biologicals can be monoclonal antibodies (mAbs) antibodies monoclonal be can Biologicals
. . (32) extra Biologicals and SMDs differ not only in terms of size, but also in how they are they how in also but size, of terms in only not differ SMDs and Biologicals Th
-
n qaiy control quality and Incontrast, biologicals are directedagainst extracellular cellor surface molecular large For other defined and independent of the manufacturing process used to create them.create to used process manufacturingthe independentof and defined in exacerbation rates exacerbation in i - ipis ht oiohlc OD a be may COPD eosinophilic that implies s . characterized and SMDs are mostly mostly are SMDs and characterized
- the same reason, biologicals cannot cross the blood brain barrier (BBB), barrier brain blood the cross cannot biologicals reason, same the umnr targets pulmonary hy are they
SMD or subcutaneous routessubcutaneous or as eemnns uh s yoie, hi rcpos r te different other or receptors their cytokines, as such determinants a s
ige oeue wt a oeua weight molecular a with molecules single
commonly i ( s e.g. usually by - (35) weight because of because ektin modifiers, leukotriene inhalation, steps a t as , ,
respectively,
central nervous system ( diitrd every administered maio o mi pamclgc hrceitc of characteristics pharmacologic main of omparison - hrpui aet ta ae yteie b living by synthesized are that agents therapeutic
sd ot for route used
hs aig h ihlto route inhalation the making thus (33) e rdcin f biologicals of production he their . hc allows which ;
h half The SMDs are SMDs - eie pyiohmcl properties physicochemical defined chemical structure or because they target they because or structure chemical when compared to their effects in severein effects their to compared when
s
allow SMD access SMD allow - ie o b of lives
ehlatie) r administered are methylxanthines) instead rdcd y hmcl synthesis chemical by produced administering
rapid a 2 - mechanistically 4 or or CNS
weeks administered once or twice or onceadministered recombinant proteins such proteins recombinant ooias r mc longer much are iologicals ) bopin and absorption .
(every 8 8 (every nege multiple undergoes < SMDs to 0 Dlo. Their Dalton. 900 and not ifrn from different
targeting like esbe or feasible weeks ne of onset
- topical bound (34) for
of ; .
This article is outcome this Acceptedin resulted trials clinical 2 phase beyond the analysis computational by development drug of toxicity immunogenicity response immune an evoke to SMDs than excretion renal or hepatic non metabolism cytochrome p450 Biologicals, administered parental to contrast Articlea have long lipophilic lower and/or activation glucocorticoids prevent structure any almost reach can and wall intestinal the inoncology and specificity high ensures non at pathways advantageous potentially be might - progression pcfc phagocytosis specific airway epithelial cells high . T 2. m The via bloodstream the into absorbed are they tract,gastrointestinal the in dissolve SMDs When biologicals therapeutic than specific less generally are SMDs
Currently, AEs to SMDs due to Currently,to SMDsdue AEs . he ytmc adver systemic c
. (32) unexpected . have SMDs inhalation, by administered When affinity for caveolaeforaffinity Nobody is perfect: atropine, relative
- – ilgcl cn e erdd n yooe after lysosomes in degraded be can Biologicals acting beta acting tbls o SD dpns n polym on depends SMDs of etabolism
protected rights by All copyright. reserved. . redundancy
r i fc caatrzd y low by characterized fact in are (40) - f ay MAP many of , whereas , biologicals have anextremely low clearance toxic strong tendency to form lipid conjugates lipid form to tendency strong ly .
lower nae anti inhaled ly levels
modest efficacy modest e fet (nie al 1 Table (Online effects se - . agonists (LABA) and muscarinic antagonists muscarinic and (LABA) agonists o
Due to Due and slow drug redistribution
f are and specificity of SMD of specificity
.
the in COPD ( COPD in Limitations
ovrey te aaiy f ilgcl t tre ige determinants single target to biologicals of capacity the Conversely, - , a type of lipid raft, further slowing drug redistributiondrugslowing furtherraft, lipid of type a , therefore ideal for ‘personalized’ or ‘tailored’ medicine ‘tailored’ or ‘personalized’ for ideal therefore kinase compensatory mechanisms compensatory ly monocyte/macrophage ucrnc d nt as the pass not do muscarinics , their longer half longer their
as have atarget
, it
o hshioiie 3 phosphoinositide Table 6 Table ff may allow inhibition of inhibition allow may
and in clinical trials clinical in . - target
The use of humanized and human mAbs human and humanized of use The critical issues related to s
)
at of part compared to compared
- (7, 8, 42, 43) 42, 8, (7, (41) effects are increasingly identified in the early stageseffectsearlyincreasinglythe are identifiedin dependent distribution. - life and size and life . . systemic rhss n mtblc nuto o hepatic of induction metabolic and orphisms . ot new Most ). However,
(37) . h bd bcue f hi small their of because body the
ytm hra SD ae lmntd by eliminated are SMDs whereas system Many factors Many , - specific , multiple isoforms, multiple ,
. kinase
resulting in high drug high in resulting
These features are sha biologicals
target iaalblt, ih laac, local clearance, high bioavailability, and t and ,
multiple BBB there is a greater risk for biologicals for risk greater a is there toxicity ( pharmacokinet , PI3K) argeting ,
biologicals and SMDs although t although idn ad internalization and binding (38, 39) (38, thus that does not dependliver not on that does - are thought to thought are eeain topical generation
,
carries ha
clinical
(or prn the sparing s
kinase significantly .
his limited specificity limited his alternative pathways alternative Ultra ) ly an
n JAK and ic relevant signaling relevant concentration
s with SMD with s increased red by the highly
- properties minimize L . ABA
contribute as evidenced as Moreover, CNS .
hampered -
s
inhibitors
chemical
( ULABA inhaled effects
ris s
s mAb
that k of k , s has
by to in in ) .
This article is subsequen with ineffective proved therapies other whom in patients some in development clinical further into proceeded time that leukotriene predominantly a mainly positioned allergicpatientswithasthma (5 lipoxygenase pathway biomarker 3 bioavailability, metabolism, clearancehalf and drugs SMDs use clinical short inmurinetumors models leukemia lymphocytic chronic and lymphoma levels IgE total that through treating 49) (48, follow ( delayed headache f well cytotoxicity ( effects immunologic other while diseases related aneffective local concentrationwith much reduced systemic exposure and AEs (44) requently reported requently .
AcceptedBiologicals and SMD Article - and tolerated with a favorablea with tolerated - up studiesup . 3.1 The
mechanisms
te imnlgcl diseases immunological other patients also in this case, this in also
[ . 210 patients/year ≤2/1000 - i.e., The off The n lwr eprtr tat infection tract respiratory lower and ae approach based
) can be can ) Following proof of efficacy in traditional asthma models asthma traditional in efficacy of proof Following Beyond main with their adminis their with
cys protected rights by All copyright. reserved. - LO) pathwa LO)
, but not all not but , is , - sc as (such - do target or indirect effects of omalizumab have been also successfully exploited for exploited successfully also been have omalizumab of effects indirect or target due t due leukotriene (LT)1 receptor antagonists and antagonists receptor (LT)1 leukotriene E seiial rltd o mAbs to related specifically AEs eitheran anti
AEs are i are not also not s
in asthma and COPD: o strategic considerationsstrategic o - inflammatory identify
( nversely associated with the risk of multiple myeloma, B myeloma, multiple of risk the with associated nversely
yet ≤ (54) good lack of of lack . 3%) immune
y - ] fully understoodfully n h 19s SMD 1990s, the In (56) driven asthma, whose phenotypic characteristics were not fully not were characteristics phenotypic whose asthma, driven AE or a desired effect desired a or AE , . (58) (46)
were introduced as the first targeted agents for systemic (oral) use in use (oral) systemic for agents targeted first the as introduced were tration profile safety The s (55) ) any associationanybetween . patient selectionpatient . (47)
Following - are injection are
antibody . complex osqety th Consequently, afetyprofile
. nie als 1 Tables Online glucocortic route, formulation, starting dose in adults and adults in dose starting formulation, route, ,
Pooled such such - -
. c registration(1999 eitd pathologie mediated eedn (DC ad complement and (ADCC) dependent
showing omparison
- (50) With o With (51 life s hoi sotnoscrnc doahc urticaria, idiopathic spontaneous/chronic chronic as - . including s site
analyses oids of . -
rather than for a for than rather . 53) (8) R
.
Ona cautionary note anti r AE are
(
reactions an reactions s cas ae nuin reaction infusion are class) a as malizumab, used in the EU since 2005, since EU the in used malizumab, : SMDs as SMDs : . B . ese
a modest beneficial effects on clinical outcomes clinical on effects beneficial modest iologicals approved for asthma iologicalsfor approved
The inhaled route for these SMDs may deliver may SMDs these for route inhaled The - Moreover, IgE plays a role in the reje the in role a plays IgE Moreover, - f IL in
it n cmae prvd ilgcl and biologicals approved compare and list rg w drugs omalizumab therapy and risk oftherapy andriskomalizumab - f lncl trials clinical of include s t 5 biological 5 herapeutic naoit o te rcioi ai (AA) acid arachidonic the of antagonists
to a lesser degree lesser a to - 2000), these2000), first forerunners d pain, asthenia pain, d ere , muoeiiy autoimmunity) immunogenicity, s, specific npyatc events anaphylactic (56, 57) (56, t s fe pecie b dfut to default by prescribed often s , at , therapeutic ettings , recent studies demonstrate leasttheir within indication and , biologicals ,
several of these SMDs these of several
(45)
observational - in , nausea, arthralgia, nausea, , inhibitors - . - - depe class agentswereclass failure cell non cell
s in are overallveryare
provides
n immune and as bearers of bearers as patients withpatients dn (CDC) ndent sometimes , malignancy
(59)
relatively of the 5 the of - mostthe Hodgkin ction of ction clear at clear 5 .
-
their year This - -
This article is approval). (pending available is which anti reslizumab, anti approved T2 scope and some including ourbeyondare diseasesthese approachesin SMD testingbiologicalclinicalandof studies description development, of phases different in COPD and therap targeted compare 6 and 5 Tables upstreamactivation events an similar mutationssomatic agent influence functions biological of spectrum is stratification patient guiding biomarkers entities on inception from based been has biologicals respectively 13, Th2 to response for indicators as selected Th2 asthma the in heterogeneity obvious less were inflammation airway targeting ( second one in volume clinical phenotypes targeted successful a of emergence for prerequisite the as recognised increasingly antibodies monoclonal of launch the delayed i aeut apoc ld to led approach nadequate
Accepted- Article high severe asthma severe high brat iae ucin s oty eodr t cmlx disease complex, to secondary mostly is function kinase aberrant - eie boakr, uh s lo esnpi cut n protn wr frhr aiae and validated further were periostin, and count eosinophil blood as such biomarkers, derived .
strategy is not directly applicable directly not is strategy
3.2 Biologicals3.2 SMDsandrefractoryfor asthma COPD:and proof While - I oncology n
and ‘Th2 xrse o T on expressed are
- subsequently high/ Th2 high/ describedin - the definition of asthma, and later COPD, COPD, later and asthma, of definition the protected rights by All copyright. reserved. g (mlzmb or (omalizumab) IgE - IL (61, (61, -
5R , of kinasesof , - discrete inflammatory
of ain stratif patient 62) bronchial -
concept studies for SMD like bronchodilators could rely on rely could bronchodilators like SMD for studies concept with mAb - low’ . h FEV1
2 recent comprehensive ned a ao dfeec bten ilgcl ad SMD and biologicals between difference major a Indeed, ratherthan genetically definedalterations
, : - the two the
n ellr n mlclr biomarkers molecular and cellular on ILC2 or
the benralizumab segregating with responsivenessto withsegregating ) Fevipiprant
epitheli other specificother eesblt a a la indicator clear a as reversibility emnto o svrl rg eeomn porm and programs development drug several of termination cells ication strategies the , um oiohl ad basophils and eosinophils ies for
- phenotypes (QAW039)
in b SMDs by d targeted biologicals, including mAbs targeting IL targeting mAbs including biologicals, targeted anti ) versus ) rncitmc intr i ptet wt mild with patients in signature transcriptomic
instead based on biologicals and SMD and biologicals on based SMD/kinase inhibitors SMD/kinase lncl trials clinical genetic biomarkers ofgenetic biomarkers patient stratification patient - IL (Figure 1) (Figure
- by by reviews biologicals 5 . new antagonists of the PGD2 receptor PGD2 the of antagonists new lagging behind lagging ,
t es 2 years 20 least at
n 09 Worf ad olaus identified colleagues and Woodruff 2009, In
timapiprant and oprd to compared
(63, 64)(63, can be drawn by drawn be can of s eeoeeu disease heterogeneous as responses to standard therap
SMD
( anti
inhaled glucocorticoidinhaled . parallel s , possibly also due to the to due also possibly , f efficacy of or or , 6, 66) (65, in
However, an s ae on based is that initially based on clinical disease disease clinical on based initially SMD - . those impacted by by impacted those severe IL setipiprant .
- .
mAb 5
-
ae en halted been have approaches,common goals R response and resistanceandresponse r vn endotype even or s ain srtfcto was stratification Patient sac o SMD on esearch
prah only approach , respectively, ,
the use of of use the asthma ht a so become soon may that boakr fr drugs for biomarkers , s
: example targeting of the
are SMDs that bind that SMDs are m forced expiratory forced epolizumab or or identification of of identification s s
ih different with s htue of use that is the FDA/EMA the
COPD, ies therapy biological a , for asthma for /
or mod - (16, 60) ih the with A . 5 and IL and 5 probably - broader
- specific CRTH2 related where erate (12) and . full . A
- , . .
This article is arachidonic acid metabolism for antagonists receptor intracellular are results antiproteinaseinhibitors) trials clinical in CSF phase 2 studies ( CXCR2predominantlythroughoccurs whichneutrophils, of phenotypesrelat and presentation clinical heterogeneous and pathophysiology complex a form comorbidities relevant clinically and infections bacterial or viral smoke), cigarette in inflammation 2) (Figure investigation receptors, activation and recruitment neutrophil Alongside t asthma patientsof forevaluationof biologicals with comparison direct a allow also would antagonists CRTH2 asthma severe eosinophilic driven, selection patient based phenotype of lack to due possibly phases, development later in failed compounds several However, T blocking mainly responses allergic recruit to and cells bronchoconstriction mast by produced prostaglandin competitively and reversibly n hymic stroma hymic
AcceptedandAZD5069)avarixinbiologicaland approaches anti (the Article -
and/ortheir receptors , omn to Common Additional targe -
c RH antagonists CRTH2 also two major areas of therapeutic unmet need unmet therapeutic of areas major two -
enzymes kit (Table 6) ting l lymphopoietin( l protected rights by All copyright. reserved.
(Tables and 5 6) seen n ms cell mast and the Tbe 5) (Table
IL biologicals
- context of of context 4R ot of most ed in this area this in sc a ihbtr o matrix of inhibitors as such , .
α .
biomarkers able toguide targetedstrategies , IL ,
are in are . O vasodilation nly recent studies finally provided finally studies recent nly
- thromboxane deemed pathogenetic in neutrophilic inflammation have underperform combinedadministration 5R ; n contrast In
several
to non
, α Tbe 5) (Table TSLP)
heightened stabilizers . phase 4 4 phase
against directed SMDs and CRTH2 B with trials of of trials with - T2, T2, iologic (72, 73) (72, ] inhibitors of other inflammatory other
h . (Figure 1 (Figure non 2 several ,
post -
(67 (76) n proof In al synthesis IgE and eosinophils cytokines, related
ae en developed been have n te Nzm treig GATA3 targeting DNAzyme the and -
2 (TXA2 A2 targetings cytokines major . oiohlc asthma eosinophilic oxidant burden oxidant -
69) - ) Hence, a Hence, marketingconfirmatorytrials ,
) although with disappointingwithalthough ) the SMDs
hrb hinder thereby - ilgcl ta ihbt etohl elastase neutrophil inhibit that biologicals MAPK of TSLP - ocp suis CT2 naoit abrogated antagonists CRTH2 studies, concept )
. te rmr pout f COX of product primary the , targeting an array of secreted metabolites and metabolites secreted of array an targeting
ealpoes (MMP) metalloprotease b
etter definition of biomarkers of response to response of biomarkers of definition etter CRTH2
and JAK
– mediators receptor
PI3K
. is the is , that
-
the CXCL2/ILthe IL E
xposure - specific + cells and a primary primary a and cells + 8 mAb, ABX mAb, 8 - / Fgr 1 (Figure hinder STAT g cell
o treat to , lucocorticoid luoye nye ivle in involved enzymes (leukocyte ucrnc eetr, histamine receptors, muscarinic [ . IgE, OX40L, IL OX40L, IgE,
activation by PGD2, PGD2, by activation –
Indeed, targeting t pathway to air pollutants ( pollutants air to indication in patients with T2 with patients in indication
suchas IL h ietfcto o discrete of identification the
- and/or , 8 receptor 8
- ih panel) right in IL severe
results for IL for results
- stable 8 s - ) - 9 resistant neutrophilic resistant are (Table have the correct the
- 1, IL 1, (77)
- 4, IL 4, hypereosinophilic COPD , with , all failed -
17, TNF 6) n of and ne clinical under - - and mainly active mainly 5, IL 5, 1 he migration . -
- . 13 trigger both dependent
h major the
D in selection 7, 71) (70, - to (74, 75) (74, ivergent 9, IL 9,
(alpha1
several PI3K COPD SMD , GM , - 13, for ed s - - - ; . .
This article is in approaches inflammatory responses of pathwaysboth receptors both blocking therefore, develop clinical of stages earlier in while 2b), (phase COPD for therapy maintenance as development under is COPD andasthma both of studies 2 phaseinresults promising yielded anti and bronchodilator synergistic Combining mo to superior was montelukast moderate with patients (NCT03112577) dupilumab investigated be to remains administration combined published been has asthma therapeutic efficacy drugs newadventof add determinants disease pathophysiology COPD and asthma biologicalSMDs’ and allow They pathological stratification patient strategies and Accepted Article - /or on
should provide should classes the
targetability of these molecules and pathways, the efficacy of of efficacy the pathways, and molecules these of targetability ment for asthma for ment Studies on association on Studies r case, this in Also F o ae n double no date, To 3.3 ih conventional with ew ht ald n rciia o ciia studies clinical or preclinical in failed that endotype n RG30, mb gis IL against mAb a REGN3500, and B examples exist of exist examples and functional and , takingadvantagethe relative, approach eachof ofstrengths iologic biologicalsand asthma and COPD and asthma protected rights by All copyright. reserved. .
al . - .
rvn ain stratification patient driven therapeutic response and s
. the
To achieve this, this, achieve To For severe asthma severe For (81) cellular and molecular biomarkers molecular and cellular - to
te than ather SMD SMD SMDs – - ln cnrle til tdig h cmiain f ilgcl in biologicals of combination the studying trial controlled blind -
u t the to due . eee sha on ta co that found asthma severe will SMD
studies of of
Moreover, ntelukast alone in improving lung function and disease control disease and function lung improving in alone ntelukast : , therapy need SMD s obnto strategiescombination despite the despite
shouldopportunities hastennew for ed isl to itself lends
evaluating the evaluating s further ih SMDs with inferring,
hoi etohlc ies determinants disease neutrophilic chronic are limited but promising: a double a promising: but limited are
ih ot of cost high s (83) ih significant with (step 5 GINA), a targeted a GINA), 5 (step . ILC2s express both cysLT1 both express ILC2s
- .
3 ad combination a and 33,
deconvolut potential advantages potential
- on nlmaoy rpris da PE/ inhibitors PDE3/4 dual properties, inflammatory necessary the ol ptnily boae h downstream the abrogate potentially could hs bases these combination will ah drug each s o du combinations drug of use .
io in hr i a rgamd td involving study programmed a is There ed o e revisited be to need glucocorticoid n that for a
by additional basic and clinical studies clinical and basic additional by sthma - diitain f olmls and roflumilast of administration rpry testing properly . , align
of lc o ptoei significance pathogenic of lack a N
biological for for COPD & evertheless SMD (82) the
(80)
with clinical presentations clinical with f h to rg fr asthma for drugs two the of this strategy this testing , -
prn effects sparing - biologicals and SMD and biologicals . inorder and CRTH2 receptors CRTH2 and
and mAb and This inhaledcombinationThis - ? blind controlled trial of of trial controlled blind
therapy is therapy h htrgniy of heterogeneity The
associations , aig no account into taking
h efc o their of effect the to – to improveoverallto – n comparing and –
: first : target lncl physio clinical, based targeted based given (78) , the non the , different
of . - severe based these as
(65) (79) T ,
he an to - - - ; . .
This article is off via indications urticaria, idiopathic chronic for omalizumab of case the in and, disease well and safe needed, much a broughthave asthma severeeosinophilic for or allergic for approved far so therapiestargeted based, clinical COPDheterogeneous and asthma of diseases complexity lung molecularinflammatory and cellular the uncovering are Conclusions associatedwith its side effects biologicals 5R been have all since disease, airways in approach this for exist (NCT02099656) proces extracellular context so approach dual effective dosage, reducing toxicity advantage and to resistance signalling downstream and cancer gefitinib/erlotinib)inhibitors, investigated a achieve and overlapping pharmacological properties of -
Accepted Articlefarelusive endotype
achieving there
s (32)
. Given Clinical and translational studies, as well as l as well as studies, translational and Clinical it may be more relevant t relevant more be may it ,
o hs n, hr ae tde fr erkzmb n obnto with combination in lebrikizumab for studies are there end, this To could replacecould conducted . verified w
/
the combination of biologicals of combination the intracellular s reduction a as SMDs T
the large the he combinationw with protected rights by All copyright. reserved.
rwh niiin f ige treatment single of inhibition growth yegsi ciia response clinical synergistic r with or - target effects target
preclinically, restorin inhibitorsby a single in the presence of high dose inhaled or oral or inhaled dose high of presence the in -
drivenpatient selection rsnain ad eadn teaetc regimens therapeutic demanding and presentations heterogeneity m oral glucocorticoid useglucocorticoidoral oeue and molecules ontelukast - target
r vn cessation even or to carry n ua tumor human in .
- . oeae tetet o ains rvosy ufrn w suffering previously patients to treatment tolerated target as superior t is that is
N o t o while aim evertheless, long evertheless, a est the combination the est ao hat ad cnmc udn worldwide burden economic and health major (NCT02104674) the may may of the
preserving efficacy g
ahas ht converge that pathways asthma and especially and asthma the the two drug classes aberrant activation of activationof aberrant addition ofaddition apply to apply (anti EGFR mAb, cetuximab) mAb, EGFR (anti o .
inhibition of proliferation of gefitinib ofproliferation of inhibition either
.
With in these patientsthese in
cell n rl prednisone oral in T o gaina specific s - Ph . a term sustainability of treatment with biologicals with treatment of sustainability term single arge
hs rationale this
o asthma for relatively
a ase -
M re biological to biological
- of of oreover, itn tmr xenografts tumor sistant scale data and computational approaches computational and data scale (85, 86) agent 3 studies of studies 3 biologicals and SMDs and biologicals
may
small
, thuscosts reducing morbidities , and , EGFR pathway EGFR of .
yielding glucocortic yet multi .
on
, Proof h combination the overcome COPD use
an rciia studies preclinical
patient pool patient common a , biologicals SMD could SMD
- hc indi which
and SMDs and have of strongerinhibition of pathophysiology - targetedapproach - ocp studies concept oids .
pathway redundancies
expanded in h fu biological four The .
no pathophysiological -
targeting . and would and For resistant cell linescell resistant in severe asthma severe in lower ae ta th that cates
n (tyrosin (84) glucocortic - hs c These overc small cell lungcell small anti t refractory ith u t their to due n oncology in
. the latter’s the its - ,
IL a different a e
Another me - original already
5 or IL or 5 need a need similar hronic kinase in EGFR oids this e the se - -
This article is keenly severeasthma, COPD or airwaywith patientstheof andwithin cells activationstructuralimmune in understanding of the humankinome CysLTs/CRTH2 (e.g. SMDs strategy such of advantages IL targeting of outcome different presentations ideal an asthma of presentations clinical specificity high for with well as drugs of class also disease development understanding and withdrawal as such thasensitivity/specificityhigher with biomarkers, to devoted asthma and SMD strategies for industry development and research for strategies preclinical D g failed disappointingly strategies, SMDs and biologicals new several while concern a remains enerally throughlack of patient stratificationand/or absence a of Accepted Articlesetbacks these espite adequateandbiomarkers in
CRTH2 antagonists having
studies needed - On the On On the On modifying therapies (55) , treatment response, optimal duration and long and duration optimal response, treatment
from eerh and research
the identification of of identification the
suggest , of d
evaluating SMDs evaluating
biomarker identification biomarker n re to order in of protected rights by All copyright. reserved. ‘right rugs rugs (92) ‘right
targeted therapies targeted biomarkers COPD and non and COPD
. n lw ie effects side low and in orderto deliver s
target drug
patient Together with formulation for the inhaled route, route, inhaled the for formulation with Together that - , many strides have been undertaken to shorten the shorten to undertaken been have strides many ,
. u
prvl f new a of approval ltimately to ltimately
’ antagonists +/ antagonists
more more side, i side, ing e effective be . . ’
targetedtherapies T To this To for for
side he adoption of he adoptionof
pathologic will basic - t is intrinsically is t T2 asthma T2 - outcome children
3 ess omn IL common versus 13 of this connection this of
d introduc for th for
– end, COPD that may that COPD ‘dare to compare’ to ‘dare /
‘ the complement full humanprotein of kinases the right drug tothe translational research translational hgl poiig agtd hrpe, prahd y both by approached therapies, targeted promising highly , to integrated to cos ifrn phenotypes different across - –
ese it H (88)
- < with specific ahas ht r a cosod o dfeet clinical different of crossroads at are that pathways 1
co e 2 years 12
rg te so the drug, end
large antagonists appropriate a uld be worthwhile be uld
and p needs to be needsto difficult to reconcile a reconcile to difficult h multifactorial the n otypes henotype/
, heterogeneous , single
biomarker increasing , also . disease recent meta recent - ,
term effects of treatment of effects term - biologicals t s rtcl o e a get to critical is It to enable to markers 13/IL - or DP1 inhibitors) DP1 or biomarkers vary over time over vary ald Vle o Death’ of ‘Valley called o complete to right endotype effectively and bioinformatics analyses bioinformatics and
approach s - receptor 4 collaboration . patient
also to also n appropriaten (91) hs wl poal be probably will These - pathogenesis
endotypic discrimination endotypic a patient and SMDs, SMDs, and nalysis nalysis -
, driven patient selectionpatient driven
r n ie phenotypes mixed in or to assess to as used fortrialsas used of
es single addressed ’ it
test combinations of several of combinations test (Table rg eeomn phases development drug .
(89, 90) (89, will enab will
As discussed As population .
o
- ewe aaei and academia between hi pit t existing to points chain
f critical period critical target In this area, i area, this In
anti
7 predictive biomarker for example for multiple parameters,multiple
epr mechanistic deeper ) n heterogeneous and .
.
, risk of relapse on relapse of risk , (87) by both biologicals both by
-
le the le IL
The requirement The approach
- - , particularly, its 5 therapies for therapies 5 through , s
, i , that lack any lack that need to be to need t would be would t biologicals deliver composite
ncreasing
between
anti and
for this for – .
ideal
- new y of y The IL the - is 5 , . ,
This article is Table Initiative companies different partnerships fostering schemes funding different among specific of development the require may combinations treatment personalized a for effect combined their of benefits interaction biologicals/SMD of knowledge mechanistic advantage the accordingly SMDs and biologicals of effects in inhibitors 4/IL ILsubunitreceptor for undertaken side effects inhibitors effective and safe
Accepted Article oncology the - 3 CXCR3/CCR6 13, 1 . present At are molecules multiple targeting inhibitors single on studies preclinical ahead, Looking
Key characteristics of asthma (97) , , so far
(9, (9, 44) in .
aeul peoye ains with patients phenotyped carefully s protected rights by All copyright. reserved.
developed for both pharmaceuticalindustry n rheumatology and f hi cmlmnay approach complementary their of . , -
however, 4R
- ilgcl ad SMDs and biologicals
and
or dupilumab
CCR3/CD300a) through
we shouldwe ih oefl anti powerful with anti
(32) - angiogenic treatment inlungcancer
,
field . Table public/private and
C also miain f t of ombination s stakeholders COPD
that 5 (93 ) learn from thefromlearn ,
with with - : 95) clearly pathophysiology - nlmaoy properties inflammatory
bi hoi nlmaoy ug diseases lung inflammatory chronic h da IL dual the n wt multi with and osri, uh s n h Invtv Medicine Innovative the in as such consortia, - otie i ti review this in outlined , specific antibodiesspecific
- niae h potential the indicate s
for example in case of compounds owned by owned compounds of case in example for
ree mb ad SMD and mAbs argeted il e eesr t explo to necessary be will preclinicalearly and
- 4/IL
in asthma and COPD and asthma in - - 3 lcig As gis their against mAbs blocking 13 agt eetr yoie kinase tyrosine receptor target (96) , (e.g. dual antagonistsdual (e.g.
that .
eeis of benefits - . phase clinicalphasestudies icmet systemic circumvent s
hud e studied be should lal, increased Clearly, re . ,
h potential the
Testing drug Testing o maximize to
synergistic
for being IL - This article is * P A A C K K P P P M M e h u u a i i e e e r r a a a t y l l a y
Acceptedw f Article v m m h i i l k n n n o i c m a d o
o o
g f w e s r y e l l e e n n o o l i i
l s n t d h l s a a g w t e k i c m y i r r y i i a e n c
y y o f p v p a i t a f t f o a e l a e e c r l a u c o r r r m r s t f t h i r n t e o s m a i i e e o p
a g n r r b a s r o
s n
h t r
n f i i p p u a l a n protected rights by All copyright. reserved. u y i d o t a l r n i n s
y c e h t n d r e c
h s a e y o s m t o i i c m i p r v o a e g f e e n l i p e o z r n
t e t n w e e o d e s n
r
o s c s s s i b o * s i o n s n t t r r u o l c l e t i d o
n t r i a S l s L u
a A b ( I P M r L e b g h - p s 4 u e L a e i / l t c a R s y A n I h u e r e L
t l e g r s l - s
e 3 e
4 i l e e p c L n i ) I v P r a R
x h o i
n T a g e r l G l α M a a E i w A a 2 n i r f m b c D c , o e n A f s t d , e s a a A
i e i I o H s g l r I b o 2 b b t r L o s s I i L r s h t r e s g / n r h t s e i l - m n b o C a y g e A i t 5 C o e s E o n m c a p m g 2 C i
h s i / R d r a c n i p ( o e n t y i n I , h p w a r e n l T t s i i L s l a f l T
l o r e l l
n e i s o n s - H s u a a o n 9 e 5 n n A t n c o y g i n 2 u
s R a s r t c - m s n s ) i s w i s l α e c o - C i i m d n t e s t a , n a o i m u
y e m s I o y s n r r l L / s t c k o A i d L b - β
n i h e 1 S k l s
l r 2 e g a v o o m r
e 3 a
u E e s c l l a r n / i o E D u k n o s n d g e o o p t d l F e e r l a
e t u t i o i e / n t b r r h
c m t h B n o d i r m e o h m e e n o r u c n r e i l r
b a t t i e s c u e l g a i i c i l c c h l c a a s M s i l
l a r c S c c S s r / o l s c c o h o r
c l o e t u i c r e e e p i d E y a s m n v n e e c L l l h s o n e c l l i i c r u o l s s c L e c l a e s g r e e s s w
T
i t e g i l r e c
n p n l i R q e P s m e e s o t l a f u u s c
e s o l p p ( l a L e a e n p r p T r t T h a m s i n p s g h o l 1 b o i , u r
t S l t
r a ( , r m g s m f b g i
o A m N S
o t u - T e ( a s 1 r a o D a O o n n e i 1
l a s c n C
d y t m t s c c u 7 A R x l c i R t i u l O L h v t s i o i t , n o B e r d a i o o a r e r i I i n o
r n t o P t 2 i a o L i s w m r
n i e r n i a
l t m C e ) m n p D a a w g v
r n e 1 i t h d r e y
n o e d s a e ,
i p v p r
f k l s I / y x
s i s a h s a i L b o s a i n i n b e C d n r r c g c o l n 3 u
e q e D e s o l r u t i d e t b s h a y f a g o l i p i c t r t o e i i a a e o d s d t n n ) i e v c s s ) e y
This article is Table T M C N U C r o l a s i i o n g m u Accepted Articlet r u i g a c t m e s r a l a
a 2 e r a l o l i s l v . g f t
n h e
y e f e
Key clinical features o a i
c r
r s p o e t r o a t u
f u o e t - c
r m e d l x h r e m y a i o o r s a c o o v r g protected rights by All copyright. reserved. e b n n n e r i a i r b o d c
r g s a i y r t e i t e i s e i e n s o l s m u p e n n r i p s r a g a h l
t c p y o a s o r n e y p
of asthma and COPD m c
u f e a a l r a i
l r r u t i i i s s o r e k k n A n S D P V A S A N N l o h o i e l b r i o o r l g m n u y e r s a t t h s o e g r - e l i i s i t g n n n a s c t r m l i
y c c a e l y t m a l
, e r r o l s i d i
e e n r e p n k a r m h a a s g i c e c n r
i r s s r e f t n i a o n e e e s i i n o x v t n i a d d e o s s i < s - t s t d i r s
i i y n
e r n n 4 m A y
a a u d
0 n n i i s t o s n r i o o y t i f k o f t l e h n n e e i o n s a - - c m r w
s s o s r t m m E s i r l a o
i
x o o o m w n
t A l k k s r d i i e e t c t e a h u r r m t s s d t i o e e
r n a
s e ,
w
i x e n a a v
T t c l e e o e n A m b r
i i r b a n p
a p c
e c t o a C A m I n M F U r n i o l E o a t h e s s l B a c
u h a V s u n t S r c r t a o u e o i 1 t m c e e a s n i c c h
r r n a l o s o d l e t o i o y e s s c i a n f e c e i e
: k s d a
t p t c t r c d e c h a u e l h i s r l i o a e e t s m o d c n e i e l l o r a n e g d
w o o a d m r r g o - k e n s t i w G i f s p i e t l s d s f e o c h e r r s a a - >
a i e s n h a v r t v i
a
l e s / a g r 4 i w s e u r d e h o d s - t 0 , a r C i
o t v o l n
t s e y l t e h y O a c
t o o i , r c r e i i n m e n a d n m P a a r c s c i o t g e e a r D e p e r r e o t s s b d e i d m i
/ p r x m o e
a s
a d i y d a l m t r e s d t g i l i e a e s s
o s o l e e s t d e u r a k n o a y a m n c e r
s c s g t i - y e e e n e h h
f l l f f s e i e u l a e s i r r t n t i c a a o u l c u t t p r s t i e r i o y , y o d e
n n ,
s
This article is Table 3 AcceptedInhaled Corticosteroids Article Systemic CS ULAMAs LAMAs SAMAs ULABAs LABAs SABAs LTRAs (ICS) a I A C M I M I I S T * M N G 5 I P L L g n n .
- n D o a o D R Y l a h e - e - E
l t
u i t n 5 5 r Current r l R S p E 3 a a m m s c u g a l R o L y t C 4 g l o B c e b e b b
a x o T c c 1 2 t E e d l r r y o n e e R a a l M g l m i r l n n u s 1 l t e A i t , e e u c l n s s
a protected rights by All copyright. reserved. / o s C - - F t a r b b c a i therapeutics s y D d o o / a b s e
A n r r u u i L
i l e / n u i T n n
c z c A i c c 1 d d u e e L l r r p e r r O r s e e t e a o X c c n r r e e 5 t
l ( p p y G t t o o a R r r p s ) for Asthma/COPD p
/ r
o v e C P M H D B M F C B Z R I T G A U I V I S O F A S L F Z M B R M O D B b p n d l i i o e e a c i a r a e r e e l m l e m r r y e i o u o r d o e e o u l l u y o f e c o e l a a r v n f u l o l n d t c f f s d t i a i n p c t m t c m m b a l d e d a d l l r d a r m h i u t n o e l r r l g r a u c o o i o o r c l t o u i m e n o c a m a l l i l u e y e t o t e o t z s i z a m o o a n a b p p e e l m m s l t z t l i l c t o k l u i n p a e i t t a s p s e o i l a n s i t u u z o i y d r e e r u o i z y u e a n e u m o c t o l i o m o a r t r u t p s r t k h n a i u r r u m n r e o e m r e s o i t m r n l o l m n n o a m t o o a d h
o a i s o m m o r t i d l r r d i a l l s e s e n o s u l o b e a t n l t s a u n e
a b o o e t e l b m ( l o s i p b
n i u a b d n
s o r n
r f
m o d i e l o u o n
u e b
m
s l r p e m u o
o
i
i t n o l a d d e
i
: s e n t i e r e p o t a approved biologicals and e r l t o B ) e d p / i f o i u o S r l n o o M a a g t t D e e i c s a I l n s d a a a a a a a a a a a a a a a a a a a a a a a a a a a C C C C C C C C C C C C C C C C C C C C C C i s s s s s s s s s s s s s s s s s s s s s s s s s s s c O O O O O O O O O O O O O O O O O O O O O O t t t t t t t t t t t t t t t t t t t t t t t t t t t h h h h h h h h h h h h h h h h h h h h h h a h h h h h P P P P P P P P P P P P P P P P P P P P P P m m m m m m m m m m m m m m m m m m m m m m t m m m m m
i D D D D D D D D D D D D D D D D D D D D D D o a a a a a a a a a a a a a a a a a a a a a a a a a a a n s M o a a a a a a a a a a a a l n n i i i i n n n n n n a a a e a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a n n n n n n n n t t t t t t t t g g g c g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g a a h h h h a a a a a a t t t t i i i i o o o u o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o SMD g g i i i i g g g g g g b b b b b b b b n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n o o l o o o o o o o o o o i i i i e i i i t i i i i i i i i i i i i i i i i i i t t t i i i i i i i i i i i i n n n n n n n n d d d d s s s o s s s s s s s s s s s s s s s s s s o o o s s s s s s s s s s s s
i i i i i i i i t t t y y y y t t t t t t t t t t t t t t t t t t t t t t t t t t t t t t t r r r r s s s s s s s s y t t t t t t t t p
e D i s c o y y n e e t s s i n u e d A F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F p D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D p F F F F A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A r D D D D / / / / / / / / o / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E A A A A v M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M e A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A d *
This article is Accepted Article Table 4 .
Comparison of SMDs and biologicals protected rights by All copyright. reserved. .
This article is Table S C I I I I I M T N O G T I I I I I I I I I I S T L L L L L L L L L L L L L g L i X S N o a X M ------4 - - e g E e 1 8 9 5 4 4 1 l r C 1 5 2 1 L 1 1 F R u 4 u l m g
AcceptedP Article / b e R 7 R R R C 3 7 3 t 0 a b e I c A r S A 2 a 1 b L L / l o t / - e F - R
r 8 p / 1 I 5 C a L / h 3 D n T -
. i C 1 e N 2 l
S 7 - 5 e B F b F A l S a iologicals under clinical investigation for Asthma/COPD o 2 F s u 4 t n a d s e protected rights by All copyright. reserved. A M R B B P D D M T G A Z O L E I G R S T I L G D C A A A E M Q V P A C L M D n M r e n i e e e t e K G r e i r G N n B B A a l a S e B u a l x o g r K t E a f a e t E b o z a a m n c o s n n 0 c e l A K c r T X K u T X r e 7 r p l 7 l p D D e n - s l i u c r u d z i o t - k a a r a l l 0 7 a x - 6 O - 6 l g 2 i p s a m 9 2 i u i e i 3 o o a I k 0 r I i I k i k k a k l k k z i s l i 1 1 8 i 7 L 9 z 4
e z 5 5 u e r 9 l a m u m i 0 l l l i u t r 2 5 i i i n i i u u i c n 8 u i i 2 u n 9 l 9 k n 4 n n 2 n z 8 8 m a 0 8 z z z m m u 6 8 a m e m a a u u u m 3 m u r 6 5 z u u c u 1 u m p 2 ( m u a a b b m m e a m m a 8 8 m V m m 2 a m a a a b t 5 b m p b a / b 6 A b b e b a a a a a a a
a t b h / K b b a b b b b b / b
u K b -
Q ( 6 M B Q 9 G 0 A a 4 E 0 X b / 0 3 5 Q
3 O 7 A 1 X 6 X 4 ) - 0 5 L 7 6 ) B i o l o g i c a l s I
n d a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
: C C C C C C C C C C C C s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s i
c t t t t t t t t O O O t t O t O t t t t O t t O t t t t t t O t O t t t t O t t O O current status h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h a P P P P P P P P P P P P m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m t D D D D D D D D D D D D i o a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a n s p p p p p M r r r r r o o o o o o t t t t t a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a r e e e e e l n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n e n n n e n n i i i i i n n n n n c t t t t t t t t t t t t t t t t t t t t t t t t t t t t t t t t t t c t t i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i . i i i
i i u b b b b b b b b i i i b b i i b b b b b b b b b b b b b b b b b b b b b b b b b b
I n n n n n l L o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o e h h h h h 4 d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d T i i i i i R y y y y y y y y b b b y y b b y y y y y y y y y y y y y y y y y y y y y y y y y y y i i i i i p t t t t t o o o o o e r r r r r D i s c o y y y y y y y y y y y y y y y y y y y y y y y y n e e e e e e e e e e e e e e e e e e e e e e e e t s s s s s s s s s s s s s s s s s s s s s s s s i n u e d S t u P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P d h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h y a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s P e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e h
2 2 1 2 3 2 3 2 2 3 4 4 4 2 2 2 2 3 2 2 1 2 3 3 1 2 3 2 2 1 2 1 2 2 3 2 2 2 1 2 2 1 a s e
This article is Table M G M p P G 5 i c P P H M T C C C I I M M S T n L L - a I - D D B R Y C o a i A l 8 4 3 t K a A l s u e M u n S R l r i r E E X T R R T K I t u m g s p s P c a
Accepted- T ArticleL 4 3 a A H 2 P t A / c / a b e J o o K c T , / m b 2 C b - A p a 2 l t c - c x e s R P 4 9 e r R / X r 3 1 e K o y l i i 1 a D 6 l C 1 g n l r n / u P n l ( G t e e R 1 0 . i T l i c e s J a d c n 2 F 2 G
A r t - o r r a SMDs a R e b
D K e i s / c b d A o 1 c 2 e e i n u e l , r R a p i / u n e p z 2 n t
c d c t e , A o d o l e r 3 e r L
r
p s P O a s u a t protected rights by All copyright. reserved. D r o X n nder clinical investigation for Asthma/COPD G r 5 d
F (
T G R y R B k 2 ) /
) N R 3 C 1
N M T P M Z I C R R J J G U S R A A T F Z P A A N A A D N S L P S C P A S V m N N o B F B H F i r F i i e i e a r o P G C Z Z Z I Z Z R l m a r e e l m m l o i K a R s y 0 - - e o J J r v f u f L T D D D D 0 6 F D a a v d 5 m 7 m 0 m 0 - - - c a i n l i 6 3 u m 5 e g - a l a 1 8 6 v m t u 3 3 1 p 2 5 1 o 7 8 0 o 1 3 4 t u l i 1 4 5 c 7 a i t p u r 0 1 2 m 8 9 r 9 i 4 0 2 c a 6 8 e 6 n r p 8 n 7 1 o i k c l 2 p i 5 4 o 1 s l i k r 3 9 a 5 7 i 8 2 6 x 3 p 2 t 3 i y 5 a a 1 i 9 n a p o t b d 9 r 5 a i d a i 2 7 l n 1 5 r 1 3 9 6 i 4 3 a a s m l 5 i 1 s r n m m i 9 r a s 4 s a 3 s o 8 8 n a t
t t n 4 8 o o / 6 t s 5 i s / e i l 1 9 i n i o b t 5 n o 3 n n t u t 8
l 5
S 6 7 t d / M 5 n 4 i / e m /
u e G 8 9 / e
Q m K K t / O f
S
i u - T Y a A l K C 7 e r o T c W 2 o 0 1 u e r H 2 a 0 e 2 t t 0 - o 6 t o 0 f 3 1 e 3 n o 9 4 n 0 9 r 5 5 i 5 d a
5 9
/ n e
7
t
s
e
t
i
p
i
p
r S a
M n
t
D
s
: c
I urrent status n a a a a a a a a a a a a a a a a a a a a a a a a a a a a d
C C C C C C C C C C C C C C C C C C s s s s s s s s s s s s s s s s s s s s s s s s s s s s i c O t t O t t O O O O t O O t t O t O O t t O t O t t t O t t t t t O t t t O t t t t t O O t h h a h h h h h h h h h h h h h h h h h h h h h h h h h h P P P P P P P P P P P P P P P P P P m m t m m m m m m m m m m m m m m m m m m m m m m m m m m D D i D D D D D D D D D D D D D D D D o a a a a a a a a a a a a a a a a a a a a a a a a a a a a n s a M p H H n p p p p p p p 3
4 4 a a a a a a a a a a a a a a a a a t o 3 3 3 3 3 3 3 D 8 i i i i i i i i i i i i i n n i i n n n n n n n n n n n n n n n l 8 8 8 8 8 8 8 s n n n a a a n n n n n n n n n a a n N α n e t t t t t t t t t t t t t t t t t e
h h h g g g h h h h h h h h h n n h h a a c i i i i i i i a a a a a a a a a a a a a a a A n n n n i n n n n i i i o o o i i i i i i i i i t t u i i g g n g g g g g g g g g g g g g g g b b b b b b b b b b b b b z b a a s h h h h h h h n n n l o o h o o o o o o o o o o o o o o o i y i i i i i i i i i i i e e i i g g i i i i i i i t t t i i i t t t t t t t t t t t n n m b b b i b b b b n n n n n n n n n n n n n n n s s s o T o o o o o o o o o o o o o o b o o i i i i i i i i i t t t i i i i i i i i i i i i i i i r y r r r r r r r r r r r n n s s r t t t i t t t t r s s s s s s s s s s s s s s s e l t o o o o o o o t t i p i i t t t t t t t t t t t t t t t o g s s r r r r r r r e r t t o D i s c o y y y y y y y y y y y y y y y y y y y y y y y n e e e e e e e e e e e e e e e e e e e e e e e t s s s s s s s s s s s s s s s s s s s s s s s i n u e d e S a P t r u P P P P P h P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P l d y h h h h h a h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h h
y a a a a a s a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a P
e s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s h P e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e a h 1
s 2 2 2 2 a 3 / 2 2 1 1 1 2 3 3 2 2 3 3 2 2 2 2 3 2 1 3 2 2 2 2 4 3 3 3 1 2 2 2 3 3 3 3 2 2 2 e 2 s
e 1
This article is ∙ Righteconomic considerations ∙ Righttreatment ∙ Rightpatient ∙ Right safety ∙ Righttarget gains from integrated therapeutical strategies Table 7 ------Accepted Article Combining intracellular and extracellular targeting: mechanisms of synergy Identification of targets useful across Better deconvolution of human kinomefor SMDs COPD Target identification inhighlyheterogenous clinical entities: non Cost Cost effectiveness calculated asthesum of immediateand long Cost reductionreversal by glucocorticoidof resistance through SMDs Cost reduction by combined biological/SMD therapy through dose term diseaserisks and complications Biologicals’ highrestrict cost their usage; alternatively, costreduction may arise by reducing long Therapeutic potential SMDsof combinations and combinations of SMDs and biologic pregnancy, Safeand effective targeted treatmentsin vulnerable patient populations: i.e., children, Assess long Explore adequate targeted treatment algorithms and treatment duration with biologicals Biomarkers for SMDs: extend searchand validation beyond thoseused for stratifications in trials Complexity adequateof biomarker identification: includemulti Defining responsivepatients L Drug Optimized pharmacology to avoid off Target liability, pharmacokinetics, pharmacodynamics, genotoxicity ong .
Biologicals and SMDs in asthma and COPD: Common critical points, unmet needs and potential - - term safety risks blockingof pathways (e drug interactions indrug combination strategies
protected rights by All copyright. reserved. -
elderly term
targeted treatment effects andrisk the of relapseon withdrawal
- multiple diseasephenotypes target activities .
. g. anti
-
eosinophil drugs)
- - omics termreductions risk - T2 and neutrophilic asthma, -
sparing
stratification tools
effects
als
- This article is have beenevaluated cell B cells, T activationof in and (MMP proteases inhibiting synthesis, (IL1R) receptor IL blocking impe drugs are investigations clinical Under neutrophils from released (MR receptors muscarinic severity irritants inhaled to macrophages lung and species oxygen of formation the causes smoke, tobacco from deriving particularly Figure2 T inhibiting by either receptor respective its strategies granule factor SMD receptors or TSLPR) cytokines associated anti and (T2)PanelLeft adrenergic asthma for therapy Standard Figure 1 Figure Legends Accepted he productionof IFN Article - based iiig hshioiie 3 phosphoinositide hibiting kit - . . tblzn agents stabilizing - -
IL ,
Current drug strategies with Currentdrug with bronchodilators acting on the on acting bronchodilators - or - receptorADRB2 8 or its receptor (CXCR2), blocking inflammatory cytokines such as TNF as such cytokines inflammatory blocking (CXCR2), receptor its or 8 5 treatment are treatment 5 strategies by .
biologicals protected rights by All copyright. reserved. ( For asthma associated with atopy with associated asthma For R meig t atvto b antagonizing by activation its impeding NS/R CXCL8 mlctd in implicated ineosinophilic COPD (
uh s SP IL TSLP, as such OS
strategies with , boxes) (green is
r TNF or targetedwith SMD )
s . under investigationunder ] .
s , mast cells and neutrophilsand cells mast ,
r t rcpo o ihbtn nurpii proliferation neutrophilic inhibiting or receptor its or , rg ipdn luoree ucin (CysLTR1) function leukotriene impeding drugs ), and and
Glucocorticoids have limited indication, mainly following exacerbations following mainly indication, limited have Glucocorticoids currently approved (all approved currently ih Pnl (Non Panel Right includes
triggers inhibitingthesynthesis of function (ALOX5)(CysLTR1) leukotrienes of .
- h/L2 cell Th2/ILC2 iae P3) et ioom p110 isoform delta (PI3K) kinase Biologicals biologicals biologicals
target the use of glucocorticoids (GR activation) (GR glucocorticoids of use the - , IL 4, chronic inflammatory responses of the airway epithelial cells epithelial airway the of responses inflammatory chronic adrenergic .
.
p120 - Approved treatments for COPD include COPD for treatments Approved mast , X0, IL OX40L, 5, have ig ooyi (C2 o nurpi rcutet by recruitment neutrophil or (CCR2) monocytic ding - T2)
lo i at aim also
and SMD and recruitment .
.
cells and refractory, hypereosinoph refractory, and target
- biologicals receptor o non For SMD 9/12) released by neutrophils and macrophagesand neutrophils by released 9/12) .
A either s ed nti s - itmn receptors histamine
for , IL 9, forCOPD
- inflammatory c block IL5, anti IL5, -
T2/non uh s CRTh2 as such 2 r etohlc asthma neutrophilic or T2 (ADRB2) (ADRB2)
- y lcig h rcpo fr survival for receptor the blocking by in blue boxes); also boxes); blue in 13 ing ), . -
their - xdns [ oxidants IL
T2 h rcutet f neutrophils of recruitment the Chronic exposure to exposureChronic - such as such a enzyme an , 13 Asthma
eetr (IL receptors and antiand ytokines such as IL ytokines such se eto 2) Section (see ,
reactive or or SABA or SABA . ,
i
drugs lic asthma lic by targeting niiig elastase inhibiting - IL targeted - - sn ms cell mast using
critical 5R
or IL or dependent on dependent
- irgn and nitrogen targeting the targeting
4R LABA, or on or LABA, ,
pollutants antibodies treatment -
1 and its and 1 : IL ,
GM .
- anti o the for are 17 and
Other - - 5R CSF - T2 IgE - . , . , .
This article is Accepted Article Figure 1
protected rights by All copyright. reserved.
This article is Figure 2
Accepted Article protected rights by All copyright. reserved.
This article is standaloneand linke healthcare and societal burden and costs asthmaof in the UK and its member nations: analyses of 6. Childhood (ISAAC). prevalence asthmaof symptoms: phaseIII theof International Study of Asthma and Allergiesi 5. Global Initiative for chronic Obstructive Lung Disease; 2018. diagnosis, management, and prevention chronicof obstructivepulmonary disease. Report: GOLD 4. tool 2016) Results. In: SeattleUSIfHMaEI, editor. Available from 3. 2017; 1990 lifeyears, and years lived with disability for chronic obstructivepulmonary diseaseand asthma, 2. 2004. 1. References Pharmacology, Clinical and Basic of Union IUPHAR, and the British Pharmacological Society, BPS International the of database the via searched were and biologicals Moreover, ClinicalTrials.gov. and EudraCT database, trials clinical European as suchdatabases the of search by and PubMed in performed was literature the of review systematic A METHODS this of Force development the in support financial their for EAACI thank to like would authors The (EAACI). Immunology Clinical and Allergy for Academy European the by financed was Force Task The Acknowledgements:
Accepted Article .; 2017. -
5 2015:systematic a analysis for theGloba report. (9):691 Mukherjee StoddartM, A, GuptaRP, Nwaru BI, Farr A, Heaven M, et al.The epidemiology, PearceN, Ait GOLD. Global Initiativefor Chronic Obstructive Lung Disease. Global strategy for the Global Burden of DiseaseCollaborative Network.Global Burden of Disease Study 2016 (GBD Collaborators GBDCRD. Global, regional, and national deaths, prevalence,disability World Health Organization, WHO.Theglobal burden of disease, 2004 update.
- 706. protected rights by All copyright. reserved.
Thorax
d national databases. - Khaled N, Beasley R, Mallol J,Keil U, Mitchell E, al. et Worldwide trends inthe
2007; 62 (9):758 - BMC Med 766. l Burden of DiseaseStudy 2015.
(10) 2016;
using COPDand asthma as keywords. 14 http://ghdx.healthdata.org/gbd
(1):113.
Lancet Respir Med
In: WHO; - - adjusted results n
SMD Task ,
-
This article is theof SPIROMICS cohort. sputumof and blood eosinophil concentrati 20. Mayo Clin Proc 19. Innovation Partnership (EARIP) Work Package(WP)2 collaborators. needsunmet inunderstanding asthma mechanisms: From the European Asthma Research and 18. 373. guidelines definition,on evaluation and treatment of severeasthma. 17. Med phenotypesusing clusteranalysis intheSevere Asthma Research Program. 16. 1807. adult asthma clusterslin 15. Respir Dis 14. 59). asthma subjects based on airway transciptomic profiles. 13. 395. inflammation defines major s 12. In: Initiative Global for Asthma.; 2018. 11. IMMUNOPHARMACOLOGY. Guideto PHARMACOLOGY in 2018: updates and expansion to encompass the newguide to 10. cytokine signaling inimmune 9. Pulmonary Disease: What theDoes Future Hold? 8. Rev Drug Discov 7.
Accepted Article
2010;
HastieAT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, et al. Association Mirza S,Ben Edwards SaglaniMR, S, Chung Wenzel KF, SE,Brozek JL, Bush A,Castro M, Sterk PJ, al.et International ERS/ATS Moore WC, Meyers WenzelDA, Teague SE, WG, H, Li X,Li et al. Identification of asthma Lefaudeux D, De MeulderB, Loza MJ, Peffer N, Rowe A, Baribaud F,et al.U Thomson NC. Novel approaches to the management of noneosinophilic asthma. S,Pavlidis Loza BaribaudM, F,Kuo C Woodruff PG, Modrek B, Choy JiaDF, G, Abbas AR, EllwangerA, al. et T GINA. Initiative Global for Asthma. Global Strategy for Asthma Management and Prevention. Harding Sharman SD, JL, Faccenda E, Southan C, Pawson AJ, Ireland S, et al.IUPHAR/BPS The Gadina Gazaniga M, N, Vian Furumoto L, Y. Small molecules to the rescue: Inhibition of Barnes PJ. Identifying Molecular Targets for NewDrug Development for Chronic Ob Barnes PJ. New anti
2016; 181 (4):315 protected rights by All copyright. reserved. 2017; 10
2013; (3):211 zo R. zo Chronic Obstructive Pulmonary Disease Phenotypes: Implications for Care. 92 - 12 323. (7):1104 ked a to subset of sputum omics. (7):543 - Lancet Respir Med 234.
- Nucleic AcidsRes inflammatory targetsfor chronic obstructive pulmonarydisease. - ubphenotypes asthma.of mediated diseases.
SchwarzeJ, Skevaki C, Smith JA, Ainsworth B, al.Addressinget - - 559. 1112.
ons ons with clinical measures COPDof severity: ananalysis -
2017; H, RoweA, Lutteret R, al. Th2 subsetting of U
2018; Semin Respir Crit Care Med J Autoimmun 5 46 (12):956 (D1):D1091 Am JRespirCrit Care Med European Respiratory Journal J Allergy Clin Immunol - 967.
201
- D1106. 7; Eur Respir J 85 Eur Respir J :20
- 31. AmJ Respir C
2015;
- 2017; helper type2
2017;
2014;
2009; 36 - BIOPRED clinical 49 (4):508
139 20 43 180 (5). rit Care Ther AdvTher 15; (2):343 (6):1797 -
(5):388 structive BIOPRED 46 - - 522. Nat driven (suppl -
- - This article is 2016; 35. ADMET& DMPK 34. forcetask paper theon use biologic of in agents allergicdisorders. 33. Cancer 32. double Benralizumab for chronic obstructivepulmonary dise 31. Eosinophilic Chronic Obstructive Pulmonary Disease. 30. asthma and chronic obstructive lung disease. 29. inSafety Moderate 28. furoate/vilanterol combination for thetreatment of stable COPD. 27. Des Devel Ther trifenatatefor the once 26. c 25. Allergy,of Asthma Immunology.& document th of medicine inpatients with allergicdiseases: Airway diseases and atopicdermatitis 24. Pulmonary Disease. 2016; 23. 1006. really exist? COPD heterogeneity and clustering in10 independent cohorts. 22. Pulmon Dis in clinical practiceaccording Spanis to 21. linical asthma phenotypes.
Accepted Article
30
- 2006; blind, placebo Mould DR, Meibohm B. Drug Development Therapeuticof Monoclonal Antibodies. Wan H. An overall comparison smallof molecules and largebiologi Boym K,Imai TakaokaA. Comparing antibodyand small Brightling Bleecker CE, ER, Panettieri RA, Jr., Bafadhel SheM, D, Ward CK,et al. Pavord ID, Chanez P, Criner GJ,Kerstjens HAM, Korn S, Lugo AL,Durham Caramori G, Chung Adcock KF, IM. Targeted anti Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, RabeKF, al. et Dupilumab Efficacyand Rodrigo GJ, Neffen H. Asystematic review with meta Albertson BullickTE, SW, Schivo M, Sutter ME. Haldar P, Pavord ID, Shaw Berry DE, MA, Thomas M, Brightling et CE, al.Cluster analysis and Muraro A,Lemanske RF,Jr., Hellings PW,Akdis CA,BieberCasaleT, TB, al. et Precision A,Comes Ianoşi Jimborean ES, G.Inflammatory Biomarkers Castaldi PJ, Benet M, Petersen H,Rafaels N,Finigan J, Paoletti M, et al.Do COPD subtypes CalleRubio M, Casamor R, Miravitlles IdentificationM. and distribution COPDof phenotypes (4):275
2017; 6 an KaegiO, Akdis C, BavbekM, S,Bossios A, Chatzipetrou A, et al.EAACI IG Biologicals (9):714 protected rights by All copyright. reserved. - 2016; e Europeane Academy Allergyof and Clinical Immunology and the American Academy 293.
2016; 12 - :2373 to
10 - - - 727. controlled, phase2a study. 4 SevereUncontrolled Asthma. :4047 - (1):1 dailytreatment asthma:of design, development and placein therapy. - 1 2383.
(1):12. Am JRespirCrit Care Med - - 22. 4060.
J Allergy Clin Immunol
h COPD Guidelines: the FENEPOC study. Transl Res Lancet Respir Med N Engl J Med aseand sputum eosinophilia:randomised, a N Engl J Med
2008; Spotlight fluticasoneon furoate/vilanterol
2016;
- 2016; molecule therapies for cancer. 178 - analysis fluticasoneof
167 137 (3):218
(1):192 Pulm Pharmacol Ther
2018; 2017; Allergy (5):1347
go N,etal. Mepolizumab for in Chronic Obstructive -
2014; inflammatory therapeutics in - 378 224. 377 - 203.
2015; cs incs ADMEtesting. 2 - (26):2486 Thorax 1358. (17):1613 (11):891
Int J Chron Obstruct 70 -
PRACTALL (7):727
2017;
- 901. - - 2496. 1629.
2017; 72 NatRev -
754. BioDrugs (11):998
42
Drug :1 - 6. -
This article is omalizumab inchronic spontaneous urticaria. 50. Allergy Clin Immunol malignancy inpatients with moderate 49. e986. the risk of malignancy: results from a pooled analysis. 4 monoclonal antibodies. 47. analysis. omalizumab inpatients with pe 46. 2017; Topical Delivery for theTreatment Inflammatoryof Diseases of the Lungs and Skin. Synthesis aof Pan 45. AnnDis Rheum 44. Am JRespirCrit Care Med 43. ChemMed 42. 41. J Pharm Pharm Sci 40. 2013; 39. Pharmacol 38. in Pediatrics. Switzerland: SpringerInternational; 2015. p. 43 and Future Glucocorticoids. In: Cimaz R, editor. Systemic Corticosteroids for Infl ammatory Disorders 37. 36. 8.
Accepted Article
60 7 :17 Kaplan AP, Gimenez A, Long Rahmaoui A, Rothman KJ, Guinan Eisner E, M, Brad BusseW, BuhlFernandez R, VidaurreBlogg C, M, Zhu J, Eisner MD, et al. Hansel TT, KropshoferH, SingerT, Mitchell JA, George AJ.safety The and sideeffects of T,Lai Wang S, ZhangXu Z, C, Zhao HuY, Y, etal. Jones StorerP, Sabnis RI, YA, WakenhutFM, Whitlock GA, England et KS, al. Design and Hammaker D, Firestein GS. upstre"Go NJ,Gross Barnes PJ. NewTherapies for Asthma and Chronic Obstructive Pulmonary Disease. MenetCJ, Rompaey LV, GeneyAdvances R. i Lou K Klein AV, Wang J,Feagan BG, Omoto Biosimilars: M. State Clinicalof and RegulatoryScience. Ejiofor S, TurnerAM. Pharmacotherapiesfor COPD. Cazzola M, Matera Novel MG. long Noce Carter PJ. Potent antibody therapeuticsdesign. by (2):767 Sci Rep -
34. 2008; 2013; ntini G, Ronchetti S,Bruscoli S, Riccardi C. ClinicalThe Pharmacology of Past, Present, -
J. SEAing changein R&D. protected rights by All copyright. reserved. - 2010; 786. 2015; 155 52 -
Janus KinaseInhibitor Clinical Candidate (PF 2017; :153
(3):291 2014; 69 Suppl 1 5 :8191. - NatRev Drug Discov 20 223.
2017; 134 (1):332 - - 299. Arnau SainiAM, SS.
(3):560 rsistent uncontrolled allergicasthma: systematic a review and meta :i77 195
- 348. - (2):159 82. - - 567 e564. to
SciBX, Science
- severe asthma treated with or without omalizumab. - - acting bronchodilators for COPD and asthma. 166.
2010; Allergy am, young man": lessons learned from the saga.p38
Mechanisms actionof that contribute to efficacy of 9 (4):325 n the discovery of selectiveJAK inhibitors.
- 2017; Business eXchange J Allergy Clin Immunol Long NatRev Immunol - 72 338. Clin Insights Med Circ Respir Pulm Med - - 58.
term efficacy and safety of (4):519 - 06263276)S
ley MS, et al. Incidence of - 533.
2012;
uitable for Inhaled and
2006; 2012; 5 (28). Omalizumab and 6 129 J Med ChemJ Med (5):343
(4):983 Br J Br - 357. - 989 J Prog
- This article is expressed on TH2 cells. activates group 2 innate lymphoid cells through chemoattractant receptor 65. Disease. 64. Opin Allergy Clin Immunol 63. 2009; Mepolizumab for prednisone 62. treatment inadults with asthma. 61. 2006; 60. Med 59. Expert Rev Clin Immunol 58. lipoxygenaseinhibitor on asthma inducedcold, by dry air. 57. Allergy 56. Database Syst Rev 55. relevantrodent model demonstratessafety of therapy usingtumour a 54. Immunol immune mechanisms linking allergy with 53. 887. AllergoOncology 52. 2018; AllergoOncology: Opposite outcomes immuneof tolerance in allergy and cancer. 51.
Accepted Article
2007; 73 360 368
1999; Xue L,Xue Salimi M, PanseI, Mjos Tripple JW, McCracken JL, Calhoun WJ. Biologic Therapy inChronic ObstructivePulmonary McCracken JL, Tripple JW, Calhoun WJ. Biologic therapy inthe ma Nair P, Pizzichini MM, Kjarsgaard Inman M, MD, Efthimiadis A, Pizzichini E, al. et Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey ArronMV, JR, et al.Lebrikizumab Wenzel SE.Asthma: defining the of persistent a Polosa R. Critical appraisal antileukotrieneof usein asthma management. DiamantZ, Mantzouranis E, Bjermer L. Mont Israel E, Dermarkarian R, Rosenberg SperlingM, Taylor R, G, Rubin etP, al. Theeffects aof 5 DiamantZ, Sampson AP. Anti FarneHA, Wilson A, Powell C,Bax L, Milan SJ. Anti Josephs NakamuraDH, M, Bax HJ, Dodev TS, MuirheadSaul G, L, et al.An immunologically Jensen Jensen Jensen (2):328 Immunol Allergy Clin NorthAm
(10):985 (9537):804 2017; 13 29 (1):24 - - - 140 protected rights by All copyright. reserved. - Jarolim E, Bax HJ, BianchiniCapron R, M, Corrig Jarolim E, Bax HJ, BianchiniCrescioli R, S, Daniels Jarolim E, Turner MC, Karagiannis SN. AllergoOncology: IgE (1 340. - 1):1449 -
the impactof allergy in oncology: EAACI position paper. 993. 2017; (4):982 - 30. -
813.
J Allergy Clin Immunol
9 2009; -
:CD010834.
- 1453. 2016; 984. - dependent asthma with sputum eosinophilia. 5
(6):639 16 N Engl J Med (4):375 -
berg JM, McKenzie AN, Spits H,et al. Prostaglandin D2 inflammatory mechanisms leukotrieneof modulators. - 658.
2017; cancerand their translational implications. - 382.
37
2014;
2011; (2):345 133 365 elukastin treatment the of asthma and beyond. dult phenotypes. - (4):1184 355. (12):1088 - N Engl J Med IL5 therapies for asthma.
anCastells C, M, al. et - - Wells TR, Dombrowicz D,al. et 1194. - 1098. -
specifi
1990;
Lancet nagement asthma.of - - Allergy homologous molecule
and IgG4 N Engl J Med 323 c IgE.c
(25):1740 Allergy
2017; Curr Opin Pulm Allergy Cochrane - J Allergy Clin mediated 72
(6):866
2018. - 1744. Clin Exp Curr
- - This article is 2014; glucocorticoid 78. Pulm Pharmacol Ther and 77. disease. deltawith theophyllinereverses corticosteroid insensitivity inchronic obstructive pulmonary 76. placebo severe,for uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double 75. 2016; replicate, phase randomised,3, double and safety of lebrikizumab in patients wi 74. obstructive pulmonarydisease. 73. Immunol pathway upregulation: relation to asthma severity, control, and inflammation.TH2 72. 2013; asthmaticallergen challengeresponse by the CRTH2 antagonist OC000459. 71. Exp Allergy selective CRTH2 antagonist, reduces allergen 70. Drugs 69. Chest 68. blind, placebo setipiprantof in seasonal allergic rhinitis: results from Phase and2 Phase randomized, 3 double 67. transmembranereceptor CRTH2. selectively induces chemotaxis inhelper T type 2 cells, eosinophils, and basophils sevenvia 66.
Accepted Article - 12 inhibitor,12 AZD1236, biomarkers on in moderate/severeCOPD: randomised a controlled trial.
41 371 4
2017; 2018; (10):781 - Bel EH, Wenzel SE, Thompson PJ, Prazma CM, KeeneON, Yancey SW, et al.Oral Dahl R, Titlestad I, LindqvistA, Wielders P, Wray H,Wang etal. M, Effects of an ora ItoTo Y, K, KizawaY, Failla ItoM, M, Kusama T, et al. Targeting phosphoinos Panettieri RA, Jr., Sjobring U, Peterffy A, Wessman P, Bowen K, Piper E, al. et Tralokinum Hanania NA, Korenblat ChapmanP, KR, Bateman ED, Kopecky P, Paggiaro P, et al. Efficacy George L, Brightling Eosinop CE. FajtML, Gelhaus SL, FreemanUvalle B, CE, Trudeau JB,Holguin F,etal. Prostaglandin D(2) Singh Cadden D, HunterP, M, PearceCollins L, Perkins M, DiamantZ, Sidharta PN, Sing White C, WrightA, Brightling C.Fevipiprantin the treatment asthma.of Bel EH, Ten Brinke Ratner AndrewsP, CP, Hampel FC, Martin B, Mo Hirai H,Tanaka K, YoshieO, Ogawa (1):46 AmJ RespirCrit Care Med controlled, phase clinical3 trials.
(13):1189 2013;
2014; 152 27 - - - (2):199 52.
sparing effect 131 protected rights by All copyright. reserved. - and active (6):1276 796. 44
(6):1504 - (8):1044 1197.
- 2012; 207. - 1282.
- referenced studies.
A. New Anti - 25 1512. - 1052. of mepolizumab ineosinophilic asthma. (2):169
Ther Adv Chronic Dis
J Exp Med
2010; h D, O'Connorh D, BJ, Zuiker R, Leaker BR, al. et - 177. - - Eosinophil Drugs for Asthma and COPD: TargetingTrait! the blind, placebo hilic airway inflammation: role inasthma and chronic th uncontrolled asthma (LAVOLTA Iand LAVOLTA II): 182 LancetRespir Med
K, KenmotsuK, K, Takamori Y, et al. Prostaglandin D2
2001; (7):897 - induced airway responsesin allergic asthmatics. Allergy Asthma Clin Immunol 193 - 904.
2016; (2):255 - controlled trials. har Bourrelly DE, etD, al. Efficacy and safety
7 (1):34
- 2018; 261.
-
PettipherR, etal. Inhibition theof 51. 6 (7):511 N Engl J Med
Lancet Respir Med -
Eur RespirJ 2017; 525.
Expert Opin Investig Setipiprant,a 13
J Allergy Clin :18. itide -
blind,
- 3
- l MMP - kinase Clin - ab - - 9 This article is microRNA combinatorial biomarkers. 91. 2018; MAP Consortium:working a model for academia 90. biomarkers. 89. 181. dimensional frameworkon R&D productivity at AstraZeneca. 88. 2013; 87. kinaseinhibitor GW572016. heregulin through heterodimerformation with ErbB3 remainsyet sens 86. Natl CancerInst 85. tyrosinekinase inhibitor. targeting theof epidermal growth factor receptor (EGFR): combining anti 84. Allergy Clin Immunol leukotriene E4 synergize to stimulate diverseTH2 functions and cell/neutrophilTH2 crosstalk. 83. Immunol cells express cysteinyl leukotrienereceptor which1, regulates cytokineTH2 production. 82. Expert Opin Investig Drugs treatment of chronic obstructive pulmonarydisease: a review of current and developing drugs. 81. 2013; chronicor obstructive pulmonary disease: findings from four clinical trials. safety of RPL554,dual a PDE3 and inhibitor,PDE4 in healthy volunteers and in patients with asthma 80. All versus montelukastalone as add 79. ergy Clinergy Immunol
Accepted Article
1 14 18 (9):714 Yang Huang Y, N,H AP, Cope Barnes MR, Belson A,Binks BrockbankM, S, Bonachela Asadullah Busch K, A, Gottwald M, Reinke P, Landeck IndustryL. Morgan P, Brown DG, Lennard S,Anderton MJ, Bar Hudson J,Khazragui HF. Into the valley death:of research to innovation. Xia W, Liu LH, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2)is regulated by Minna JD, Peyton MJ, Gazdar Huang S,Ar L,Xue Fergusson J,Salimi M, I,Panse Ussher JE,Hegazy AN, et al. Prostaglandin and D2 Doherty TA, Khorram N, Lund S,Mehta AK, Mulhall AM, Droege CA,E Franciosi LG, DiamantZ, BannerKH, Zuiker R, Morelli N, Kamerling IM, et al. Bateman ED, Goehring UM, Richard F, Watz H. Roflumilastcombined with montelukast (1):53 (13
2013; - 14):610 Nat R - - 60. 727. 132 protected rights by All copyright. reserved.
2005;
ev Drug Discov (1):205
mstrong EA, Benavente S,Chinnaiyan HarariP, PM. Dual - 613.
2015; 2016; 97 (16):1168
CancerRes -
213. 135 138 2015; ao L, Kong Aclustering W. Oncogene (1):142 (5):1358
24 -
2015; on treatmenton inpatientswith moderate rnstNE, Panos RJ,Zafar MA. Phosphodiesterase4 inhibitors for the - 1169. (12):1597
2004; BMC Genomics - AF. Gefitinib versus cetuximab inlung cancer: round one.
149 e148. 14 - 2004; 1366 e1351
(12):805 64 23 - (15):5355 1611. (3):646
- industry collaboration. - 806.
CroftM, Broide LungDH. type innate2 lymphoid - 1311.
- 2017; based approach for efficient identification of - -
653. 5362.
rett JC,Eriksson U, et al.Impactof five a 18
Nat Rev Drug Discov (Suppl 2):210.
itiveto thedual EGFR/ErbB2 - - NatRev Rheumatol academia collaborations for - Capdevila F, et al.RA The - EGFR antibody with to LancetRespir Med
- - agent molecular severeasthma. Drug Discov Today
2018; Efficacy and 17 J Allergy Clin (3):167
J
J J - - -
This article is Initiative (IMI). severerefractory asthma: an international consensus statement fromInnovative the Medicine 97. kinaseinhibitors novel as anti 96. 2006; byasthma bispecific a antibody fragment linking CCR3 to CD300a. 95. bispecific antibody for effective dual targeting of CXCR3 and CCR6. 94. J Respir Cell Mol Biol antagonist reduces lung inflammation, airway hyperresponsiveness, and IgEpr 93. 2018; Perspectives, Opportunities, an 92.
Accepted Article 118 78 Bel EH, Sousa A, Fleming L, Bush A, Chung Versnel KF, J,al. et Diagnosis and definition of Wang J,Zhang L, Pan X, DaiSun B, Y, C,Li et al. Munitz A,Bachelet I,Levi RobertJuglair R, LimL, EX, AngWang C, CJH, EbertG, al.A fullyet humanized IgG Kasaian MT, Marquette K, Fish S, DeClercq C, AgostinelliCook R, TA, etal. An IL Wilson LJ, Linley A, HammondHood FE, DE, Coulson JM, MacEwan DJ, et al.New (1):15 (5):1082 - 29. protected rights by All copyright. reserved. Thorax -
1089.
2013;
2011;
49 66 (1):37 - angiogenesis agents. (10):910 d Challengesin ExploringHuman the Protein Kinome. - Schaffer F.Reversal airwayof inflammation and remodeling in - 46.
- 917.
Sci Rep Discovery of multi
2017;
7 :45145. J Allergy Clin Immunol PLoS One -
target receptor tyrosine
2017; oduction in mice. 12 (9):e0184278. Cancer Res - 4/IL
- like - 13 dual
Am